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ABSTRACT 
POTENTIAL ENHANCEMENT OF DIETARY ISOTHIOCYANATES COMBINATION  
ON BIOLOGICAL ACTIVITIES 
 
MAY 2017 
 
KANYASIRI RAKARIYATHAM, B.S., CHIANG MAI UNIVERSITY, THAILAND 
 
M.S., CALIFORNIA STATE UNIVERSITY FULLERTON 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Hang Xiao 
 
Isothiocyanates (ITCs) such as allyl isothiocyanate (AIT) and sulforaphane (SFN) are well-
known bioactives with wide range of beneficial properties, which may be consumed 
simultaneously through diets containing cruciferous vegetables. However, biological activities of 
ITCs in combinations had not been well defined. The present study evaluated the potential 
efficacy of AIT, SFN and their combinations on three important biological properties: anticancer, 
anti-inflammation and antioxidant. 
Our results showed that the combination between AIT and SFN led to a stronger growth 
inhibition on A549 non-small cell lung cancer cells than treatments with the individual 
compounds. The enhanced effect was proved to be synergistic by isobologram analysis. Flow 
cytometry analysis demonstrated that the combination treatment caused more extensive cell 
cycle arrest and cellular apoptosis in the cancer cells than the singular treatment. In addition, a 
synergy between AIT and SFN was also observed in their anti-cell migration. It is noteworthy 
that the AIT-SFN combination resulted in the production of intracellular reactive oxygen species 
(ROS), which might contribute to their inhibitory effects on cancer cells.  
In terms of anti-inflammation, the combination of AIT and SFN both pairing between 
themselves (AIT-SFN), and pairing with other dietary bioactives (AIT-CUR, AIT-LUT, and SFN-LUT) 
 vii 
enhanced this beneficial property in comparison to a single compound utilization in 
lipopolysaccharide-induced RAW 264.7 macrophages. We observed dose-dependent and 
synergistic inhibition of pro-inflammatory molecules production such as nitric oxide, and 
interleukin-6. Western blotting showed corresponding information that the combined 
treatment reduced the expression levels of pro-inflammatory proteins and increased the 
expression of an antioxidative protein, which could contribute to their anti-inflammatory 
properties as well. 
In addition, pretreatment of RAW 264.7 cells with the AIT-SFN combination provided 
synergistic cytoprotective effects against tert-butyl hydroperoxide-induced oxidative damage by 
increasing antioxidant effects, decreasing cellular ROS, and increasing viability of RAW 264.7 
cells. These protective properties were completed through phase 2 antioxidant and 
detoxification proteins, some of which had more dominant effects than the others, under a 
partial regulation of Nrf2, and NF-B transcription factors. 
Overall, this study proved a potential enhancement of dietary ITCs in combinations on 
biological activities, and provided information for developing functional foods for health 
benefits.  
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CHAPTER 1 
 
INTRODUCTION 
Cancer is a major public health problem with high death rates in many parts of the 
world. Although many techniques and therapies have been utilized to treat cancer, malignant 
cells may reduce their dependence on one hallmark capability and become more dependent on 
another, generating a status called drug resistance. This is because each of the hallmark 
capabilities is regulated by redundant signaling pathways and cancerous cells can undergo 
adaptation by mutation, epigenetic reprogramming, or remodeling of the stromal 
microenvironment (1). Recently, there has been a growing body of evidence suggesting that the 
combination of cancer chemopreventive agents may enhanced treatment efficacies through 
distinct mechanisms (2). Among combinatorial treatments, utilizing dietary bioactive 
components are of interest due to their none or few adverse effects and their multi-targeting 
features, leading to reduction of side effects and minimizing the development of drug resistance 
(3). 
To date, little is known about the roles of dietary bioactives in combinations, which 
represents a complex system including consumption of fruits and vegetables mix.  The present 
study was undertaken to evaluate the enhanced beneficial effects of dietary phytochemicals, 
particularly allyl isothiocyanate (AIT) and sulforaphane (SFN), both of which are isothiocyanates 
(ITCs), when they were combined together, and when each of them was combined with other 
dietary bioactives such as luteolin (LUT), and curcumin (CUR). These bioactive compounds were 
chosen based on their biological properties and their sources which are natural diet-based.  
ITCs are naturally occurring molecules found in cruciferous vegetables from enzymatic 
conversion of glucosinolates. They are suggested to be promising anticancer agents. Many of AIT 
and SFN have displayed anticarcinogenic activities through various mechanisms including 
 2 
reducing activation of carcinogens, reducing cancer cell proliferation, inducing cycle arrest 
leading to apoptosis, and decreasing invasion and metastasis (4, 5). Besides, they also possess 
anti-inflammatory and indirect antioxidant properties through regulations of well-known 
transcription factors nuclear factor-B (NF-B), and nuclear transcription factor erythroid 2p45 - 
related factor2 (Nrf2), respectively. Since ITCs have been proved to act through several 
mechanistic targets, this attribute of the compounds may be effective and suitable for the 
combinatorial therapeutic approach. 
Polyphenols such as LUT and CUR can be found in a range of plant foods including 
oregano, and turmeric, respectively. They possess direct antioxidant properties regarding their 
chemical structures, that are capable to donate hydrogen or electron and stabilize a radical 
species, as well as to bind transition metal ions such as iron and copper. They also have been 
shown to exert strong indirect antioxidant by increasing activation of Nrf2. Their anti-
inflammatory activities can be achieved via suppressing the activation of NF-B and activator 
protein-1 (AP-1) (6, 7). In addition, several mechanisms have been revealed in the cancer 
chemopreventive activity of LUT and CUR including inhibition of angiogenesis, and induction of 
apoptosis via reactive oxygen species (ROS) accumulation (8-10). 
Regarding studies that reveal connections between oxidative stress, inflammation and 
their deleterious effects on cancers (11), the present work studied chemopreventive effects, 
anti-inflammatory properties, as well as the cytoprotective effect of AIT and SFN in combination. 
In addition to the AIT-SFN combined treatment, other phytochemicals including LUT, and CUR 
were also used to combine with the aforementioned bioactives and tested on their enhanced 
anti-inflammatory properties. This project has a long-term goal to comprehend, and emphasize 
the significance of using dietary phytochemicals in combinations for formulating and developing 
functional food products that improve cancer prevention. The overall objective of this project is 
 3 
to enhance biological activities of anticancer, anti-inflammatory, and antioxidant properties 
using dietary bioactive agents in combinations, including co-treatment of AIT and SFN. The 
rationale of this research is from the distinct mechanisms of each bioactive compound that may 
support each other’s effects when using in combination. Based on this rationale, our central 
hypothesis is that a combination of dietary ITCs can enhance biological activities that are 
anticancer, anti-inflammation, and oxidative damage prevention. To determine how any two 
substances, act together, we consider the value of the combination index (CI) from isobologram 
analysis, whether it is < 1, = 1, or > 1 so we know that the compounds are acting in synergistic, 
additive, or antagonistic pattern, respectively. This hypothesis can be proved through the 
following directions:  
Specific Aim 1:  To study combinatorial effects between AIT and SFN on 
chemoprevention 
AIT, SFN, and their combination in dimethyl sulfoxide (DMSO) vehicle will be used to 
treat A549 non-small cell lung cancer cells, followed by cell viability determination. To find out 
how the treatments work according to the reduction of cell proliferation, cell cycle arrest and 
apoptosis were examined using flow cytometry. Cellular ROS was measured using 
dichlorofluorescein diacetate (DCFH-DA). Cell migration was also observed through a scratch 
assay as an indicator of anti-metastatic property. To confirm and support the result, molecular 
studies of protein expression was determined using Western blotting. 
Specific Aim 2: To study combinatorial effects between AIT and SFN on anti-
inflammation 
Anti-inflammatory effects of single and combined treatments between AIT-SFN, SFN-
LUT, AIT-LUT, and AIT-CUR were in vitro determined in lipopolysaccharide (LPS)-induced RAW 
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264.7 macrophage model. Molecular studies of protein expression, and inflammatory cytokines 
were determined using Western blotting, and ELISA techniques, respectively.  
Specific Aim 3:  To study combinatorial effects between AIT and SFN on prevention of 
chemical-induced oxidative damage 
Cell viability was measured in RAW 264.7 macrophages pre-treated with AIT and SFN as 
a single or a combined treatment before being exposed to an oxidant, tert-butyl hydroperoxide 
(t-BHP). To investigate how bioactive compounds work together as antioxidants, cell viability, 
intracellular ROS, total glutathione (GSH), cellular glutathione-S-transferase (GST) activity, as 
well as the activation of key transcription factors (Nrf2, and NF-B), and phase 2 antioxidant 
proteins were determined. 
This study would have significant impact on an improvement of prevention and therapy 
of cancer, and other diseases related to inflammation and oxidative stress. The knowledge from 
this work will be fundamental for further bioactives and/or drug combination study and for 
developing functional food to improve health benefits. 
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CHAPTER 2 
 
LITERATURE REVIEW 
2.1 Overview of Cellular Oxidative Stress, Inflammation and Carcinogenesis 
In cellular systems, oxidative stress can increase the production of inflammatory 
mediators and initiate or promote carcinogenesis. Extensive studies have revealed the 
mechanisms of oxidative stress, inflammation, and carcinogenesis as well as explanations of 
how they are associated with one another. At the molecular level, key transcription factors such 
as NF-B, Nrf2, and STAT3 are considered as linkers since they are found to be active during 
these processes.  
2.1.1 Oxidative Stress 
Oxidative stress is an imbalance between a production of oxidants or reactive oxygen 
species (ROS) and their eliminating factors known as antioxidants. Superoxide anion, hydroxyl 
radicals, hydrogen peroxide, nitric oxide, and singlet oxygen are examples of ROS. Under normal 
conditions, some of these ROS have functions in cell signaling and homeostasis. However, under 
stresses, there is an overwhelming of ROS leading to damages of biomolecules such as DNA, 
proteins, and lipids with potential influence on the whole organism (11).  
Lipids, especially polyunsaturated fatty acids-containing multiple double bonds are 
attractive to ROS. Free radicals such as hydroxyl radical are very reactive and not stable. They 
obtain single electron from lipid molecule to make themselves more stable and generate 
lipoperoxyl radicals which is an initiation of lipid peroxidation. During propagation, lipid radical 
reacts with another free fatty acid, producing a different fatty acid radical and a lipid peroxide. 
Malondialdehyde (MDA) which is a mutagen is also being generated during this process. 
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Moreover, physiological properties of lipid-containing organelles such as cell membrane 
integrity and permeability could be altered when lipids are modified (12, 13). 
Similar to lipid peroxidation, when free radicals attack proteins, they generate radicals 
on peptide molecules particularly on side chains of amino acids which can react with oxygen to 
yield peroxyl radicals following with the consequences that change and end with MDA 
production (14).  
Free radicals, especially hydroxyl radical, can hydroxylate either a purine or a pyrimidine 
base in DNA to generate radicals.  8-hydroxyguanine radicals made by an interaction between 
hydroxyl radical and the base guanine could undergo further reactions, including a reaction with 
oxygen, to generate a guanine peroxyl radical.  Once the DNA base is damaged, a strand of DNA 
breaks because hydrogen bond linking between bases can no longer occur.  DNA damage is 
harmful because DNA is a template for gene replication and transcription and thus protein 
synthesis as a downstream process. It causes errors in signal transduction affecting cell functions 
and causes mutations associated with carcinogenesis (15).  
 These are only examples showing how deleterious of oxidative stress is. In fact, 
overwhelming ROS affect to other more biological molecules and the severity of the injury 
depends on the type and concentration of particular ROS.  
2.1.2 Inflammation 
Inflammation is a physiological process of organisms to physical, chemical 
or biological stimuli as an adaptive response to restore homeostasis. The controlled 
inflammatory response is beneficial to the host. For example, it protects the host against tissue 
irritation, injury, or infection. However, it can become unfavorable when it is dysregulated, 
causing septic shock or leading to many disorders and diseases, such as cancers, metabolic 
disorders, neurological disorders, cardiovascular diseases, and chronic inflammatory diseases 
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(Figure 2.1). A successful acute inflammation eliminates infectious agents follow by tissue 
repairing. If the acute inflammation is not successful to eliminate pathogen or any source of 
tissue damage, including autoimmune disease or undegradable foreign bodies, the 
inflammatory process persists and turn to a chronic inflammation.  
 
 
 
Figure 2.1 Acute and chronic inflammation. Adapted from (16). 
 
 
Inflammatory process composts of complex regulatory networks that includes inducers, 
sensors, mediators, and effectors. The combination of each component determines the type of 
inflammatory response. Inducers initiates inflammatory responses by activating specialized 
sensors which then stimulate the production of specific mediators altering functionality of 
tissue.  
Inflammatory inducers can be exogenous and endogenous. Examples of exogenous 
inducers are toxic compounds, foreign bodies, allergens, irritants, and microbes either 
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pathogenic or non-pathogenic. Endogenous inducers are signals being produced by stressed, 
damaged, and/or malfunctioning tissue.  
Inflammatory mediators can be categorized into seven groups based on their 
biochemical properties: vasoactive amines, vasoactive peptides, fragments of complement 
components, lipid mediators, chemokines, cytokines, and proteolytic enzymes. Many mediators 
not only affect their target tissues but also induce production of additional mediators.  
Inflammatory effectors are cells and tissues that are specifically affected by the 
inflammatory mediators. Responsiveness to certain mediators are varied. They have distinct 
effects in different tissues and cell types as an adaptation to maintain homeostasis against 
noxious conditions (17).  
 
2.1.3 Carcinogenesis 
Carcinogenesis is a process which normal cells are transformed into cancer cells. There 
are three distinct steps in this process which are initiation, promotion, and progression.  
Initiation happens when mutations occur in critical genes such as genes regulating cell 
cycle checkpoints which are important in controlling proper cell division. When these genes are 
mutated, cells lack an ability to detect malfunctions and pass through cell cycle or cell division, 
carrying the mutations to the new cells. The results of the initiation step can be little or even no 
observable changes in morphology of cells or tissues. It does not confer a permanent increase in 
susceptibility to cancer formation.  
Tumor promotion appears when there is disruption of non-mutagenic tissues by 
wounding or inflammation. The result in non-malignant tumors, which may regress with no 
further stimulus. It is an epigenetic process meaning a change in genetics that is not influenced 
by DNA sequence manipulation.  
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Tumor progression is a process transforming benign tumors to malignant tumors. There 
are some further genetic mutations as well as tissue disruption involved. Without requiring 
external stimuli, the mutated cells can generate angiogenesis to support an increase of size and 
numbers of cells, resulting in a bigger tumor, a so-called tumor microenvironment composed of 
multiple distinct cell types. Eventually, they can create capability for tissue invasion and 
metastasis which is a distant development of secondary malignant tumor growth from the 
primary site (18). These are also multiple steps beginning with the local tissue invasion, followed 
by intravasation in which cancer cells invade through membranes of nearby blood and lymphatic 
vessels. After that, the cancer cells escape from the lumina of both vessels to the parenchyma of 
distant tissues (extravasation), form small nodules (micrometastases), and finally grow from 
micrometastatic lesions to macroscopic tumors also known as colonization. 
 During the multi-step development of tumors, there are different hallmarks such as 
sustaining proliferation signaling, evading growth suppressors, resisting cell death, enabling 
replicative mortality, inducing angiogenesis and activating invasion and metastasis. These 
hallmarks rationalize the complexities of neoplastic disease or cancer. These events are 
underlined by genomic instability leading genetic diversity which in the end expedites their 
acquisition and inflammation which fosters the functions of mentioned hallmarks.  
 Sustaining proliferative signaling is the most fundamental trait in cancer cells. They do 
not have controls, as do the healthy cells and tissues do. In general, normal tissues control the 
production and release of growth-promoting signals that instruct cells to the enter cell cycle 
division through checkpoints in order to find and fix genetic mistakes if any or to send them to 
apoptosis if the mistakes cannot be fixed. This is to ensure homeostasis of cell numbers and 
maintain regular tissue functions. Unlike normal cells, cancer cells dysregulate these signals and 
enable cell growth in sizes and numbers. Alternatively, cancer cells may send additional signals 
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to normal cells within the supporting tumor-associated stroma to sustain more on various 
growth factors. In addition, the receptors of these growth factors can be elevated in numbers 
which increases chance of binding and rendering hyper responses without limitation. 
Evading growth suppressors is another point which cancer cells must circumvent to 
sustain cell proliferation. Tumor-associated protein p53 is a tumor suppressor that regulates 
circuits governing decisions of cells to either proliferation or senescence activation and 
apoptosis. It receives signal from stress and abnormality sensors functioning in the cells. If the 
degree of genomic damage is excessive, p53 can call a pause to further cell cycle process until 
the condition is normalized or it can trigger apoptosis in the case of non-fixable damage. 
Therefore, dysregulation of p53 would support the result of cell proliferation increase. 
 Resisting cell death is a process that favors cancer development by regulating apoptosis. 
There are two simple concepts for the regulation. First, the limitation of apoptosis happens with 
the losing of p53 tumor suppressor that eliminates sensors of cell critical damage, thus mutated 
cells are not sent to apoptosis machinery and survive. Alternatively, increasing of anti-apoptotic 
proteins as well as their regulators expression by downregulating pro-apoptotic factors or by 
short-circuiting the extrinsic ligand-induced death pathway support cancer development as well.  
 Enabling replication immortality can be achieved by extending telomeric DNA, which is a 
region of repetitive sequences of nucleotide at each end of a chromosome. During chromosome 
replication, enzymes that duplicate DNA cannot continue their duplication until reaching the 
end of a chromosome, leading to more and more shortening of the chromosome in every 
duplication. Telomere protects the end of the chromosome from deterioration including end-to-
end fusion with neighboring chromosome so cells can grow and pass through division cycles. 
There is an association between telomere length and cancer risk. In cancer cells, long-length, 
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repeating segments of telomere are added to the end of telomeric DNA by telomerase, which is 
a specialized DNA polymerase and bring about unlimited replication potential of the cells. 
 Inducing angiogenesis happens in cancer cells during tumor progression. An “Angiogenic 
switch” is activated almost all the time and remains constantly on, causing normally quiescent 
vasculature to develop new vessels which help sustaining neoplastic growth. This is different 
from normal cells where angiogenesis is transiently on only when necessary such as during 
wound healing and reproductive cycling in females. Angiogenesis can be regulated by vascular 
endothelial growth factor-A (VEGF-A) and thrombospodin-1 which are well-known prototypes of 
angiogenesis inducers and inhibitors, respectively.   
 Activating invasion and metastasis are processes that promotes tumor progression. 
Cancer cells develop changes in shapes and their attachment to other cells as well as to 
extracellular matrix. Cancer cells lose the function of E-cadherin, which assembles epithelial cell 
sheet and maintain the quiescence of cells within these sites. Therefore, cancer cells are 
detached and capable to delocalize to distant target organ (1). 
2.1.4 Association between Cellular Oxidative Stress, Inflammation, and Carcinogenesis 
Oxidative stress has been implicated in many pathological conditions such as 
cardiovascular diseases, neurological disorders, diabetes, and cancers. These diseases can be 
classified into two groups. The first group is diseases involving mitochondrial oxidative stress, 
which is caused by pro-oxidants shifting the thiol/disulfide redox state and impairing glucose. In 
this case, the oxidative stress from overwhelming ROS can trigger an inflammatory response. By 
contrast, the second group of diseases involves inflammatory oxidative conditions in which 
inflammation contributes oxidative stress in cells. In the case of cancer, cellular condition 
involving oxidative stress and inflammation may lead to cellular transformation from being 
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normal to cancerous through continuous stimuli. One piece of evidence is redox imbalance in 
cancer cells that contain higher ROS level than normal cells (12, 19). 
Accumulating data support that tumors can originate at the sites of inflammation 
(Figure 2.2), especially the chronic type that leads to cancer. For example, the development of 
carcinomas in the gastrointestinal tract is attributed to Helicobacter pylori- induced gastric 
inflammation. Patients suffering from inflammatory bowel diseases such as ulcerative colitis and 
Crohn’s disease have higher risk to develop colorectal cancer. During inflammation, various 
inflammatory innate immune cells generate ROS, which are chemical effectors in inflammation-
driven carcinogenesis. Therefore, one of the possible mechanisms is that the generation of ROS 
in inflamed tissues causes DNA damage and leads to activation of oncogenes and /or 
inactivation of tumor suppressor genes. 
Chronic inflammation is associated with all stages of carcinogenesis (initiation, 
promotion, and progression). Their progressions are proceeded by remarkable molecular 
players known as inflammatory mediators such as cytokines, chemokines, and regulators of 
prostaglandins and nitric oxide production pathways.  
Inflammatory cytokines can be soluble proteins secreted from cells to extracellular 
space or they can be membrane-bound small proteins expressing as the immune response. 
Cytokine signaling is initiated when cytokines bind to their cell-specific cognate receptors on cell 
membrane followed by activation of intracellular kinases cascades with subsequent activation of 
transcription factors predominantly STAT3, Nrf2, and NF-B which together regulate 
physiological processes including oxidative stress, inflammation, and carcinogenesis. 
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Figure 2.2 Involvement of inflammation in carcinogenesis. Adapted from (20). 
Chemokines are soluble chemotactic cytokines, which are classified into four major 
groups such as CXC, CC, XC, CX3C based on the positions of conserved cysteine residues. During 
chronic inflammation, they are produced by pro-inflammatory cytokines. Chemokines have a 
central role to recruit leukocytes at the site of inflammation. CXC and CC are common in tumor 
cells with different selectivity for particular leukocytes. For example, both CXC and CC attract 
lymphocytes. Only CXC attracts neutrophils. Similar to cytokines, chemokines also initiate their 
signal by interacting with specific receptors. They involve in cell proliferation, invasion, and 
metastasis of different tumors (21). 
Regarding the association between inflammation and oxidative stress, there is an 
accumulation of the ROS during inflammation which activates cellular survival signaling 
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pathways including nuclear factor-B (NF-B) and the upstream kinase cascades which are 
known to have crucial roles in inflammation, immunity, cell proliferation and apoptosis (11). 
Under normal conditions, the transcription factor NF-B is inactive in a complex form with its 
inhibitory molecule (IB) in the cytoplasm. However, it is activated during inflammation through 
the phosphorylation process, which dissociates NF-B and IB from the NF-B - IB complex. 
Phosphorylated-IB (p-IB) is subsequently ubiquitinated and degraded by proteasomes. 
Activated NF-B translocates into the nucleus and upregulates the expression of numerous 
target genes including inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and 
inflammatory cytokines (22, 23). The enzyme iNOS produces nitric oxide (NO) via the conversion 
of arginine to citruline, in which excessive NO involves mutagenesis, tumerigenesis, and 
carcinogenesis. Similarly, COX-2 catalyzes a specific step in biosynthesis of prostaglandins (PGs), 
some of which, especially PGE2, are associated with cancer (24). Pro-inflammatory cytokines, 
such as interleukin-1 (IL-1) and interleukin-6 (IL-6), also play key roles and are elevated in 
inflammatory conditions (25). However, cells have phase 2 antioxidant and detoxification 
proteins including heme oxygenase (HO)-1 regulated under the nuclear transcription factor 
erythroid 2p45 - related factor2 (Nrf2) (26). This enzyme catalyzes degradation of pro-
inflammatory free hemes and catalyzes the production of anti-inflammatory and antioxidant 
molecules (27). NF-B does not only regulate inflammatory response, but also regulate 
apoptosis. It has a dual role to either inhibit apoptosis through induction of survival genes 
including B-cell lymphoma-extra large (BcL-xL) or to promote apoptosis when working along 
with activator protein (AP-1) to induce expression of Fas ligand which belongs to the tumor 
necrosis factor (TNF) family (28). 
When ROS and inflammatory signals are continuously prolonged, disorders, including 
carcinogenesis follow. In cancer cells, Signal transducer and activator of transcription3 (STAT3) is 
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constitutively active due to the aberrant activity of the upstream signaling proteins of STAT3 
such as endothelial growth factor receptor (EGFR), HER2, Src and JAK2. STAT3 activation is 
linked to malignant cancer behaviors, including growth, epithelial-mesenchymal transition, 
migration, invasion, metastasis and therapeutic resistance. In cell survival, STAT3 positively 
upregulates survivin, B-cell lymphoma (Bcl)-2 and Bcl-xL which are anti-apoptotic proteins to 
repress apoptosis (29, 30). In fact, apoptosis can be both negatively and positively regulated. 
Another transcription factor, p53, is known to upregulate apoptosis upon the increase of its 
expression through the downstream proteins such as cleaved caspase-3, and poly (ADP-ribose) 
polymerase (PARP) (31). However, induction of STAT3 by expression of v-Src was shown to 
suppress p53 levels resulting in more cell survival. The transcription factor p53 not only 
regulated apoptotic event, but also cell cycle arrest. It could signal growth arrest of cell at a 
checkpoint to allow DNA damage to be repaired before DNA replication or to lead cell arrest 
before entering mitosis and undergo apoptosis when the damage was irreparable (31, 32). This 
information reinforces on-going cancer when p53 is downregulated. During angiogenesis and 
metastasis, STAT3 activation elevates expression of MMP-2, MMP-9 and VEGF. Matrix 
metalloproteinase (MMP) carries metalloproteinase activity which plays a role to degrade 
vascular basement membrane and of basic fibroblast growth factor, and VEGF, which are 
important in vascular endothelial cell proliferation and facilitation of cell penetration through 
extracellular matrix (33). Besides cell survival and tumor progression, STAT3 also regulates 
inflammation. It has two different roles to upregulate either pro- or anti-inflammatory cytokines 
depending on cellular conditions.  
As mentioned, oxidative stress, inflammation, and carcinogenesis are regulated through 
complicated networks. There are many transcription factors involved in a mechanistic pathway 
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and a transcription factor can control more than one pathway, suggesting association among 
oxidative stress, inflammation, and cancer. 
2.2 Possible Preventive and Therapeutic Mechanisms 
Depending on the association among oxidative stress, inflammation and cancer, 
changing at least one process could significantly affect the rest. Therefore, elimination of an 
overwhelming ROS and prolonged inflammation could prevent initiation and promotion of 
cancer. However, in the case of malignant tumors, increased ROS could lead to programed cell 
death known as apoptosis. Decreasing inflammation would reduce angiogenesis thus tumor 
growth is not accelerated (21). Consequently, the loop of sustained “inflammation-cancer-
inflammation” is no longer present. This information leads to a strategy to use combined 
treatments to eliminate inflammation and to selectively regulate oxidative stress for cancer 
prevent and therapy.   
2.2.1 Antioxidation 
Antioxidants act differently in the defense systems. The first level is preventive 
antioxidants, which suppress formation of free radicals. For examples, glutathione peroxidase, 
glutathione-S-transferase are known to decompose lipid hydroperoxides which are prone to 
initiating radical formation. The second level is antioxidants that scavenge active radicals to 
reduce ROS chain initiation and/or stop propagation reactions such as vitamin C and vitamin E. 
The third level is the repair and de novo antioxidants, which include proteolytic enzymes in 
cytoplasm and mitochondria. They recognize, degrade and remove oxidatively modified proteins 
(34). 
Based upon the source, antioxidants can be classified as endogenous and exogenous 
agents (Table 2.1). Endogenous antioxidants include enzymatic and non-enzymatic molecules.  
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Table 2.1 Classification of antioxidants (Adapted from (35)) 
Classification Antioxidant 
Based upon their nature - Enzymatic antioxidant: SOD, CAT, GPx, and GR 
- Non-enzymatic antioxidant:  
- Metabolic antioxidant: GSH, Lipoic acid, L-arginine, 
Bilirubin, Metal-chelating proteins, Transferrin 
- Nutrient antioxidant: Vitamin E, Vitamin C, Trace metals 
(Selenium, Manganese, Zinc), Flavonoids, etc 
Based upon source - Endogenous antioxidant: Bilirubin, GSH, Lipoic acid, NADPH 
and NADH, enzymes (SOD, CAT, GPx, GR) 
- Dietary antioxidant: Vitamin C, Vitamin E, Carotenoids, 
Polyphenols 
- Metal binding protein: Albumin (Copper), Metallothionein 
(Copper), Ferritin (Iron), Myoglobin (Iron), etc 
Based upon mechanistic 
action 
- Catalytic systems to neutralize or divert ROS: SOD, CAT, 
GPx 
- Binding/inactivation of metal ions: Ferritin, Catechins, etc 
- Self suicidal and chain breaking antioxidant: Vitamin C, 
Vitamin E, GSH, Flavonoids 
 
Superoxide dismutase (SOD), glutathione peroxidase (GPX), glutathione reductase (GR), catalase 
(CAT), and heme oxygenase (HO) are the major antioxidants in the cells. SOD catalyzes 
dismutation of superoxide anion into oxygen and hydrogen peroxide. There are three isoforms 
of SOD in humans, which are cytosolic copper and zinc-containing SOD (Cu/Zn-SOD), manganese 
requiring mitochondrial enzyme (Mn-SOD), and extracellular Cu/Zn-SOD (EC-SOD). GPX converts 
a glutathione (GSH), a tripeptide-containing glutamate, cysteine, and glycine, to oxidized 
glutathione known as glutathione disulfide (GSSG). During this process hydrogen peroxide and 
lipid hydroperoxides are converted to water and corresponding stable alcohol, respectively. GPX 
has isozymes in cytoplasm, mitochondria, and extracellular compartment. CAT also dismutates 
hydrogen peroxide to water and oxygen. GR reduces GSSG to GSH as a recycling antioxidant 
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system. HO catalyzes degradation of heme and generates carbon monoxide (CO), biliverdin, and 
iron. HO and its product CO have a cytoprotective effect against oxidative stress. Two distinct 
isoforms of HO are HO-1 and HO-2. HO-2 is constitutively expressed while HO-1 is inducible.  
Endogenous non-enzymatic antioxidants such as glutathione, thioredoxin (Trx), and 
melatonin are found in mammals. Glutathione, generally reduced form (GSH), is one of the key 
antioxidants present in the body. It is ubiquitously expressed together with three other enzymes 
which are GPX, glutathione-S-transferase (GST), and, GR. Trx system is composed of Trx and 
thioredoxin reductase (TrxR). Trx is a disulfide-containing oxidoreductase that modulates redox 
sensitivity of transcription factors. It can be found in cytoplasm, mitochondria, membrane, and 
extracellular space. Reduced Trx has active dithiol groups which can scavenge ROS and maintain 
proteins in their reduced states. After acting as an antioxidant, reduced Trx becomes oxidized 
Trx which can then be reduced again by TrxR and NADPH. Melatonin is a hormone synthesized 
from serotonin primarily in the pineal gland, but it is also produced in the retina, lymphocyte, 
gastrointestinal tract, and bone marrow. It is ubiquitous and effective in both aqueous and lipid 
phases to neutralize free radicals such as hydroxyl radicals, peroxyl radicals, superoxide anion, 
and hypochlorous acid. Unlike other antioxidants, oxidized melatonin is irreversible and is 
referred as a suicidal or terminal antioxidant. 
As mentioned, regulation of ROS can also be achieved by modulating antioxidant 
proteins. Potency of the endogenous antioxidants is regulated by specific transcription factor. 
For example, Nrf2-Keap1 pathway responds to xenobiotics and eliminates oxidant. Nrf2 is a 
transcription factor that modulates expression of genes coding for detoxification enzymes and 
antioxidant proteins. Kelch-like ECH-associated protein or Keap-1 is a cysteine rich protein which 
in its dimeric form interacts and sequesters Nrf2 in the cytoplasm, thus inhibiting transcriptional 
activities. In response to attack by electrophiles, which can be ROS or any bioactive compounds, 
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Nrf2 can be switched on and off via distinct mechanisms. Oxidative modification of Keap1 and 
Nrf2 phosphorylation results in releasing of Nrf2 from Keap1. Free Nrf2 translocates into the 
nucleus, binds to antioxidant responsive elements (AREs) involving activation of antioxidant and 
detoxification gene expression, and results in cellular protection from free radical damage (36).  
Vitamins, minerals and other bioactive compounds from fruits and vegetables are 
examples of exogenous antioxidants. Ascorbic acid or vitamin C is a primary antioxidant in 
plasma. It donates electrons to other molecules and protects them from oxidation. Vitamin E, 
especially α-tocopherol, which is the most biologically active form, protects cell membrane from 
lipid oxidation. It terminates the lipid oxidation process by donating an electron to scavenge 
lipid peroxyl radical and becoming a less reactive radical which can be recycled to the reduced 
form later on with the help of other antioxidants. However, α-tocopherol can also reduce iron 
and copper which are pro-oxidants. Therefore, α-tocopherol has dual roles as either anti-or pro-
oxidant, which varies case by case depending on the amount of α-tocopherol available to 
scavenge ROS, as well as a reduction potential of α-tocopherol compared to other molecules 
present in the system. Minerals including zinc (Zn), copper (Cu), manganese (Mn), iron (Fe), and 
selenium (Se) are important elements of antioxidant enzymes by acting as cofactors such as Fe-
requiring catalase, Cu/Zn-SOD, Mn-SOD and Se-GPX. Plant bioactives such as polyphenols have 
demonstrated for their antioxidant properties by different mechanisms including radical 
scavenging, metal binding, upregulating expression of antioxidant proteins as well as increasing 
antioxidant enzyme activities. 
 
2.2.2 Anti-Inflammation 
Because of the key role of the transcription factor NF-B in induction of pro-
inflammatory genes, affecting various cells involved in immune response, NF-B has become an 
attractive target to therapeutically control inflammation. Referring to the activation of NF-B 
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pathway, inhibitory B (IB) would be phosphorylated by IB kinase (IKK) and free NF-B from 
the NF-B - IB complex to translocate into the nucleus for upregulation of inflammatory 
related genes, while IB in the cytoplasm is ubiquitinated and degraded by proteasomes. Since 
NF-B pathway is composed of a number of discrete steps, different inhibitors, for which more 
detail will follow, act differently with respect to their specific targets in the pathway.  
IBα super-repressor is an IBα protein with mutations at serine residues 32 and 36. 
This mutation leads to the incapability of the protein to be phosphorylated by IKK, providing a 
consequence of not being degraded and retaining NF-B in the cytoplasm. In addition, this NF-
B repressor enhances the sensitivity of cells to apoptosis inducing stimuli. Therefore, no 
prolonged inflammatory signal occurs. 
Glucocorticoids inhibit NF-B pathway through diverse mechanisms. Prednisone and 
dexamethasone are common ones that are widely used for their anti-inflammatory and 
immunosuppressive properties. Dexamethasone induces expression of IB upon mRNA and 
protein level to enhance the cytosolic retention of NF-B. However, there are other mechanisms 
by which dexamethasone represses IL-6 expression and p65 NF-B-dependent transactivation 
without changing IB protein level.  
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, sodium salicylate, and 
sulfasalazine are used to treat chronic inflammation. Aspirin and sodium salicylate suppress IB 
phosphorylation by inhibiting IB kinase (IKK) activity with inhibition of ATP binding to IKKβ. 
Another related aminosalicylate derivative, mesalamine, prevents IL-1-mediated stimulation of 
p65 phosphorylation. Thus, different NSAIDs inhibit NF-B pathway at multiple steps.  
Immunosuppressive agents, including cyclosporine A and tacrolimus are used in organ 
transplant to prevent graft-versus-host disease. They are non-competitive inhibitors of 
chymotrypsin-like activity of the 20S proteasome. Therefore, they prevent IB degradation and 
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inhibit NF-B from activation. They can also directly inhibit NF-B activity by modifying cysteine 
residue in the activation loop of IKKβ. 
Cyclopentenone prostaglandins induced by COX-2 are involved in the resolution phase 
as regulators of inflammation and immune responses. They exert their anti-inflammatory 
properties through the activation of peroxisome proliferator-activated receptor (PPAR)- which 
is a member of nuclear receptor super family. Additionally, these PGs can directly inhibit NF-B. 
One of the cyclopentenone PG metabolites, PGA1, inhibits TNF-α-induced phosphorylation of 
IBα by inhibiting IKKβ activity with the cysteine residue modification, NF-B DNA binding, and 
NF-B transactivation. 
Peptide aldehydes such as MG101, MG132, and MG115 inhibit protease activity of 
proteasome thus they prevent IB degradation and NF-B activation. 
Natural products have biological activities to inhibit NF-B pathway. For example, 
flavonoids, quercetin, and resveratrol downregulate NF-B, providing a consequence of fewer 
downstream inflammatory mediators, including NO, and inflammatory cytokines. 
A better understanding of the regulation of inflammation, including NF-B pathway may 
provide opportunities to develop treatments. Although NF-B is currently an important target to 
reduce an overwhelming inflammatory response, it may be not appropriate to block the NF-B 
pathway for prolonged periods since it also plays a pivotal role to maintain host defense to 
bacterial and pathogenic infection. However, short-term treatment might be necessary and 
might also reduce side-effects (28, 37).  
 
2.2.3 Anticancer 
Studies of cancer hallmarks as well as their association with inflammatory signal and 
oxidative stress have extended our understanding in biological complexity of cancer and bring us 
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to develop treatments based on their mechanisms of action. This method promotes 
development of drugs that have specific activities against a target while having relatively fewer 
off-target effects.  
It is widely accepted that cancer prevention is preferable to therapy. Therefore, it is 
reasonable to redox balance with the help of antioxidants, not letting ROS overwhelm and cause 
oxidative damages to biological molecules which is prone to cancer initiation. At the same time, 
active carcinogens causing mutation can be detoxified by host phases 2 antioxidant and 
detoxification enzymes such as glucuronidases, and sulfotransferases and excreted to the urine 
(38). In addition, prolonged inflammation also generates ROS and links to cancer. Thus, 
eliminating inflammation represent a valid strategy for cancer prevention as well as therapy. In 
cancer therapy, there have been many cases facing adverse effects from using anticancer drugs 
including toxicity to both tumors and host tissues, and toxicity arising from the accumulation of 
the agent in a particular region such as the cardiovascular system and liver. These side effects 
limit dose utilization and efficacy of the agent. Application of an anti-inflammatory agent with 
anticancer drug can reduce this toxicity problem and enhance the therapeutic effects by acting 
either additively, synergistically or sensitizing the conventional anticancer agent. For example, 
combining celecoxib with docetaxel decreased hematologic toxicity in prostate cancer patient. 
Other NSAIDs particularly aspirin may aid in preventing arterial thromboses, allowing an 
anticancer agent to reach microscopic tumor foci more easily and improve the effect in the 
patient. Although the anti-inflammatory agents do not change the pharmacokinetics of the 
anticancer drug, they may affect its metabolism, leading to alterations in concentration, half-life, 
and clearance of the active metabolites and consequently modify toxic doses and efficacy (39).  
When a mutation occurs, cells have mechanisms to check and repair DNA damage 
through cell cycle arrest. Cells with irreparable damage are sent to programmed cell death to 
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terminate replication of genetic errors. Cells are shifted towards a more oxidizing environment 
with higher ROS, leading to apoptosis and necrosis. Based on this nature of host to eliminate 
cancer cells, a unique “oxidation therapy” was introduced. ROS generating enzymes such as 
glucose oxidase and xanthine oxidase are directly delivered or induced in tumor tissue using 
anticancer drugs fabricated with polymeric micelles or nanoparticles known as enhanced 
permeability and retention-effect. Another approach is to decrease antioxidative systems in 
tumors using inhibitors of antioxidant enzymes such as zinc protoporphyrin IX, an HO inhibitor. 
Regarding ROS and cancer, it should be noted that different levels of oxidative stress affect 
cancer differently. Low or intermediate level of oxidative stress cause DNA damage, mutation, 
inflammation inducing carcinogenesis while high oxidative stress leads to programmed cell 
death. Thus, it is practical to counter balance of cellular ROS to either prevent or to treat cancer 
depending on stages of cells (38).  
Furthermore, mechanism-based targeted therapies have promoted drug development 
that can be classified regarding their effects on one or more hallmark capabilities. For example, 
EGFR inhibitors, cyclin-dependent kinase inhibitors, pro-apoptotic mimetics, telomerase 
inhibitors, inhibitors or VEGF signaling, and inhibitors of HGF/c-Met are used to treat against 
sustaining proliferative signaling, evading growth suppressor, resisting cell death, enabling 
replicative immortality, inducing angiogenesis, and activating invasion and metastasis, 
respectively. However, it is also important to consider compensation pathways. Since each of 
the core hallmark capabilities is regulated by partially redundant signaling pathways, inhibiting 
at only one target is not enough. Furthermore, it cannot completely shut off the hallmark 
capability, and initiates an adaptive response which causes resistance to the treatment. 
Therefore, the design of treatment protocols to selectively co-target at multiple cores may 
result in more effective therapy for human cancer (1).  
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2.3 Dietary Bioactive Components Against Oxidative Stress, Inflammation and Cancer 
Fruits, vegetables, and grains have beneficial effects against disorders and diseases 
including cancer. These protective roles are mainly attributed to the presence of 
phytochemicals. There are many types of phytochemicals including tannins, curcuminoids, 
flavonoids, triterpenoids, steroids, saponins, and alkaloid. These bioactives possess a range of 
biological activities whose mechanistic actions help in preventing and/or treating diseases (40). 
The effectiveness of these compounds may result from their use in monotherapy or in 
association with other compound(s) in combinations. The latter approach may provide an 
optional strategy to enhance therapeutic efficacies against oxidative stress, inflammation, and 
cancer.  
 
2.3.1 Roles of Some Phytochemicals 
Phytochemicals can reduce cancer risks by blocking initiation and suppressing later 
stages, including promotion, progression, angiogenesis, invasion, and metastasis. Many of them 
can alter metabolisms of procarcinogens to detoxify and excrete the toxic substances from the 
body. Some of them have antioxidant activity to scavenge free radicals and reduce oxidative 
stress. These efficacies in phytochemicals could prevent mutation which is an initiation stage of 
cancer. Anti-inflammatory property of phytochemicals can also prevent tumor development. 
They are sometimes used as a co-treatment to suppress or eliminate tumor cells with other 
compounds possessing capabilities to inhibit growth by induction of cell cycle arrest and 
apoptosis (41). Specific detail of particular phytochemicals (Table 2.2) will be followed.  
 
2.3.1.1 Isothiocyanates 
Isothiocyanates (ITCs) are a group of compounds found mostly in plants, principally cruciferous 
vegetables such as broccoli, cabbage, and kale. Some marine sponges and fungi also 
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Table 2.2 Chemical structures of selected phytochemicals 
Phytochemical IUPAC Name Chemical Structure 
Allyl 
isothiocyanate 
3-isothiocyanatoprop-
1-ene 
 
Sulforaphane 1-isothiocyanato-4-
methylsulfinylbutane 
 
Luteolin 2-(3,4-
dihydroxyphenyl)-5,7-
dihydroxychromen-4-
one 
 
Curcumin (1E,6E)-1,7-bis(4-
hydroxy-3-
methoxyphenyl)hepta-
1,6-diene-3,5-dione 
 
 
 
have been reported to produce ITCs. In plants, ITCs are synthesized and stored as glucosinolates 
(β-thioglucoside N-hydroxysulfates). When there are damages in plant tissues, glucosinolates 
are released and converted to ITCs with the catalysis of myrosinase, an enzyme that coexists in 
the plant but they are stored separately. Besides plants, gut microflora can also produce 
myrosinase to hydrolyze glucosinolates from vegetable consumption. Glucoraphanin and 
sinigrin are glucosinolates with different side chains that will be converted to sulforaphane (SFN) 
and allyl isothiocyanate (AIT), respectively. 
Previous studies showed that the amount of ITCs available most likely depended on 
myrosinase activities in the vegetables. Since myrosinase is heat-labile, the bioavailability of ITCs 
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from cooked broccoli is less than the amount of from fresh ones. In addition, intestinal 
microflora myrosinase may only hydrolyze small fractions of glucosinolates ingested (42).  
ITCs rapidly accumulate in all tested human and animal cells. They penetrate into a cell 
by diffusion and quickly metabolized through the mecapturic acid pathway. Initially, there is a 
conjugation with intracellular GSH, the most abundant thiols in the cell found to be a driving 
force for ITCs accumulation. Glutathione-S-transferases (GSTs) enhance the accumulation by 
promoting the conjugation reaction. Sequentially, the conjugates undergo enzymatic 
modification to form cystenylglycine, cysteine, and N-acetylcysteine (NAC) conjugates. The level 
of ITCs accumulation can reach millimolar concentration range before being rapidly exported at 
least partly by membrane transporters including multidrug resistance associated protein-1 
(MRP-1) in urine. Approximately, 72% of a single consumption of SFN was recovered in rat urine 
as NAC conjugates in 24 hours and only 1% was detected in the second 24 hours (42, 43). Similar 
to SFN, the bioavailability of AIT is high with nearly 90% of orally administered substance was 
absorbed. The average concentration of AIT after 24-hour single consumption was 10 times 
higher in urine in comparison to the concentration in blood (44). This information indicates that 
both SFN and AIT can be quickly absorbed and urinary eliminated almost entirely within 24 
hours after ITCs consumption. 
2.3.1.1.1 Sulforaphane 
Some cruciferous vegetables contain high content of a certain glucosinolate and the 
corresponding ITC. For example, broccoli sprouts contain around 74% glucoraphanin of all 
glucosinolates present in the sprouts. Relatively less or no detectable amount of indole and β-
hydroxyalkenyl glucosinolates that are associated with potential toxicities. In other words, SFN 
can be particularly found in broccoli and broccoli sprouts in high levels. This is an important 
information since some ITCs possess stronger effects than others.  
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SFN exerts its protective effects through distinct mechanisms. One of them involves the 
direct detoxification of carcinogens by inhibition of phase 1 enzymes of the cytochrome P450 
system. Phase 1 enzymes occur when ligands bind to the aryl hydrocarbon receptors and the 
complex is transported into the nucleus to bind the xenobiotic responsive element which is the 
DNA region upstream of cytochrome P450 genes. This system usually relates to oxidation, 
reduction, and hydrolysis which generally lead to xenobiotics detoxification, but are also 
involved in the conversion of procarcinogens to carcinogens that can bind to critical molecules 
including DNA. SFN inhibits some, but not all cytochrome P450 enzymes (CYPs) by different 
mechanisms. For example, it is a competitive inhibitor of CYP2E1 in microsomes from livers of 
acetone treated rats to inhibit genotoxicity of N-nitrosodiummethylamine. In human liver, SFN 
decreases CYP3A4 mRNA, protein expression, and enzyme activity probably through xenobiotic 
receptor without affecting CYP1A2. Therefore, SFN prevents formation of carcinogen-induced 
DNA-adducts, which is an important step in blocking tumor initiation.  
In addition, SFN is a potent inhibitor of heterocyclic amines which are mutagens derived 
from cooked meat. Toxicity from 2-amino-1-methyl-6-phenylimidazol[4,5-b]pyridine (PhIP), the 
most abundant type of heterocyclic amines, can be significantly reduced with SFN treatment. 
This protection was not attributed to modulation of CYP1A2 levels, but was ascribed to the 
induction of phase 2 detoxification enzymes which convert carcinogens to inactive metabolites 
that are readily excreted from the body thus preventing DNA damage. Phase 2 enzymes such as 
glutathione S-transferases (GSTs), UDP glucuronosyltransferases and gamma-glutamylcystein 
which is a rate-limiting enzyme in GSH synthesis, are induced via the binding of Nrf2 at 
antioxidant responsive element (ARE). SFN increases phase 2 enzymes by reacting with specific 
thiol groups on Keap-1 and form thionacyl adducts promoting dissociation of Nrf2 from Keap-1, 
and allowing subsequent activation of ARE-driven genes. Notably, the induction of these 
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carcinogen blocking genes by SFN is Nrf2 dependent. Without this transcription factor, the 
upregulation of these genes are blunted.  
Since Nrf2 regulates both detoxification and antioxidant genes, Nrf2 activation by SFN is 
also indirectly involved in the elimination of ROS by enhancing the antioxidative cellular activity 
of phase 2 antioxidant enzymes such as NAD(P)H quinone dehydrogenase (NQO-1), thioredoxin 
(Trx) reductase and HO-1. Additionally, SFN induces antioxidant enzymes to counteract cellular 
susceptibility to oxidative stress due to the decrease of cellular thiol groups, especially GSH, 
from binding to SFN molecule itself.  
Besides blocking mechanisms, SFN also has mechanisms to deal with post-initiation 
stages of carcinogenesis by decreasing and/or eliminating tumors. It induces cell cycle arrest 
predominantly at G2/M phase, but other phase arrest is possible as well, depending on the dose 
and duration of SFN treatment. In human colon carcinoma Caco-2 cells, G2/M phase arrest were 
observed with 20 µM SFN treatment, but higher concentration than that could induce 
accumulation of sub-G1 cells and loss of mitochondrial membrane potential. In addition, p21 
protein, a tumor suppressor that plays an important role in cell cycle arrest, was found to be 
increased in expression with SFN treatment in both in vitro and in vivo. 
Administration of SFN induced apoptosis as indicated by cleaved PARP. In colon cancer 
cells HCT116, 15 µM SFN induced an activation of caspase-7, caspase-9, and apoptosis-
independent p53, while it decreased the expression of B-cell lymphoma-extra large (Bcl-xL). 
There was also a release of cytochrome C from mitochondria. In prostate cancer cells PC-3, the 
induction of apoptosis was associated with caspase-3, caspase-7, and caspase-9 activation with 
an increased Bax : Bcl-2 ratio. Correspondingly to the in vitro experiment, a PC-3 xenograft 
experiment demonstrated that SFN administration in vivo could significantly inhibit tumor 
growth by reducing tumor volume and weight, and increasing Bcl2-associated X (Bax) protein 
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expression level. Therefore, it is clear that SFN induced apoptosis in prostate and colon cancers 
through both death receptor and mitochondrial pathways.  
SFN has also been implicated in the modification of histone acylation, a process 
controlling gene expression at the chromatin structure, by inhibiting histone deacetylase 
(HDAC). Increased HDAC expression and activity are common in many cancer malignancies. SFN 
treatment in human embryonic kidney 293 cells and colon HCT116 decreased HDAC activity and 
increased acetylated histones H3 and H4 in both cell lines. This HDAC inhibition was attributed 
to SFN metabolites, SFN-cysteine, and SFN-NAC, which are generated after the conjugation of 
SFN with GSH. In mice given a single oral dose of SFN or SFN-NAC, HDAC inhibition and p21 
induction were observed with concomitant increased acetylated histones. Therefore, inhibition 
of HDAC is associated with a SFN-mediated cell cycle arrest and apoptosis, which in turn limits 
tumor growth. 
As a “suppressing” agent of carcinogenesis, SFN also has anti-inflammatory properties 
to decrease inflammatory mediators which are tumor promoting factors. SFN has been shown 
to down-regulate at the transcriptional level lipopolysaccharide (LPS)-mediated induction of the 
expression of iNOS, and COX-2 and the secretion of TNF-α in RAW 264.7 macrophage cells. The 
activation of NF-B, the transcription factor in this inflammatory response, was found to be 
decreased. SFN could either directly inactivate NF-B by binding to essential cysteine residues at 
thiol groups or indirectly by interacting with GSH and/or other redox regulators such as Trx 
which are relevant for NF-B function.  
SFN exerts not only the direct effects on tumor cells, but also influence the growth of 
established tumors by inhibiting angiogenesis and metastasis. In immortalized human 
microvascular endothelial cells HMEC-1, SFN dose- and time-dependently inhibited hypoxia-
induced mRNA expression of VEGF and angiogenesis associated transcription factors, hypoxia-
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inducible factor-1 alpha (HIF-1α) and c-Myc. It could affect the inhibition of basal membrane 
integrity by reducing production of MMP-2 and reduction of cell proliferation, migration and 
tube formation.  
In summary, the anti-carcinogenic action of SFN is wide-ranging, involving detoxification 
of carcinogens, an increase of cellular antioxidants, direct cytostatic action on tumor cells, 
inhibition of angiogenesis, metastasis and inflammation (45-47). 
 
2.3.1.1.2 Allyl Isothiocyanate 
AIT, also known as mustard oil, is one of the most common naturally occurring ITCs. Its 
parent compound, sinigrin, is particularly predominant in mustard, horseradish, and wasabi as 
well as in commonly consumed vegetables such as Brussels sprouts, and cabbage. AIT is in liquid 
form at ambient temperature with melting point at -80 °C. It has a very pungent taste due to its 
activation of transient receptor potential A1 channel in sensory neurons. In plants, AIT serves as 
a defense to repel herbivores. Sinigrin is mixed with plant myrosinase and converted to AIT as 
the herbivores chew the plants. 
AIT inhibits proliferation of various cancer cells with low IC50 values in the micromolar 
range, even in drug resistant cells that overexpress drug transporter MRP-1 or Pgp-1. AIT 
treatment is dose- and time-dependent. Interestingly, AIT is significantly less toxic to normal 
cells. For example, 40 µM AIT exposure for 24 hours resulted in 36-38% human prostate cancer 
cell survival whereas normal human prostate epithelial cells were viable as much as 83% 
AIT has provided anticancer activities not only in cell cultures, but also in animal models. 
In PC-3 xenografted mice, three times per week of AIT treatment (approximately 333 µmol/kg 
body weight) inhibited tumor growth by approximately 45% with no apparent toxicity. Although 
sinigrin was found four times more effective than AIT, both of them significantly reduced the 
number of aberrant crypt foci in colonic mucosa of dimethylhydrazine-induced Wistar rats. 
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AIT can inhibit cancer cell growth through induction of cell cycle arrest and apoptosis. 
Similar to SFN, AIT could cause as high as 80% cell cycle arrest in either G1 phase or G2/M 
phase.  For example, human leukemia HL60 cells were arrested in G1 phase while bladder 
cancer UM-UC-3 were arrested in G2/M phase.  
The exposure of 10 µM AIT for 24 hours to HL60 cells induced nearly 30% apoptosis, 
which was associated with disruption of mitochondrial transmembrane potential, activation of 
several caspases, including caspase-3, caspase-8, caspase-9, and caspase-12, and activation of c-
Jun N-terminal kinase (JNK). AIT also induced apoptosis in PC-3 cells, which was associated with 
downregulation of anti-apoptotic Bcl-2 and Bcl-xL as well as an activation of extracellular signal-
regulated kinase and JNK. Nevertheless, AIT was not a good apoptosis inducer in some cancer 
cells, such as HT29 cells and UM-UC-3 cells with less than 5% apoptotic cells found after 
treatment which probably due to the dose of treatment.  
Besides cell cycle arrest and apoptosis induction, AIT also influences the growth of 
cancer cells by increasing histone acetylation. Its concentration at 20 µM was shown to 
stimulate acetylation in mouse erythroleukemia DS19 cells without inhibiting histone 
deacetylase, which is different from SFN that can inhibit the enzyme in cancer cells. 
Both AIT and its NAC conjugate (AIT-NAC) at the concentration range between 0.1-5 µM 
have been reported to significantly inhibit the transcription of MMP-2 and MMP-9 in human 
hepatoma SK-Hep-1 cells which are associated with the inhibition of cell adhesion, migration 
and invasion.  
AIT also demonstrates its anti-inflammatory property by inhibiting NO and decreases 
the expression of iNOS in LPS-induced J774.1 macrophage at concentrations less than 10 µM. In 
HT29 colon cancer cells, higher AIT concentration between 25-100 µM could inhibit NF-B 
activation, which was stimulated by LPS. 
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In addition to mechanisms defending against tumor initiation, AIT has cytoprotective 
properties through the induction of the cellular antioxidative system. AIT has been shown to 
induce several phase 2 antioxidant and detoxification enzymes such as NQO-1, HO-1, and GST in 
both in vitro and in vivo through Nrf2 activation. 
Overall, AIT exhibits desirable attributes for cancer prevention and inhibition including 
high bioavailability after oral administration, rapid uptake by cells, induction of the antioxidant 
protective system, and specific cell toxicity in malignant cells than in normal cells. However, AIT 
doses in the preclinical studies are far greater than the amount that normally people are 
exposed to, raising the question whether dietary consumption of AIT could significantly 
contribute to cancer prevention in human or should there be any strategy to make a benefit out 
of dietary AIT. Therefore, further studies are necessary. So far, the most exposed to orally 
administered AIT resulting from its specific elimination through the urine suggest that AIT may 
be most useful for bladder cancer prevention (44). 
 
2.3.1.2 Luteolin 
Luteolin (LUT) is a flavone. It is one of the most common flavonoids found in many 
plants in both aglycone and glycosides. Their dietary sources include celery, carrots, olive oil, 
oregano, peppers, peppermint, rosemary, and thyme. These glycosides usually have sugar 
moieties at positions 5, 7, 3’ and 4’, through one or several free hydroxyl (OH) groups on LUT 
molecule. Scolymoside (LUT 7-O-rutinoside), and cynaroside (LUT 7-O-glucoside) are examples 
of LUT 7-O-glycosides. Besides, O-glycosides, sugars can also be bound through a C-C bond. 
Common C-glycosides of LUT are LUT-8-C-glucoside (orientin) and LUT 6-C-glucoside 
(isoorientin) (8). 
LUT has sufficiently high bioavailability and its metabolism is sufficiently low to allow 
exertion of biological activities. LUT aglycone can be absorbed after oral administration and LUT 
 33 
7-O-beta-glucoside was also absorbed after being hydrolyzed to LUT by intestinal microbacteria. 
LUT aglycone is converted to glucuronide, or sulfate-conjugates during passing through the 
intestinal mucosa (48). It was passively absorbed more efficiently from the jejunum and 
duodenum than from the colon and ileum. The plasma concentrations of LUT depends on the 
form of LUT ingested. The free form of LUT was observed in human plasma after LUT 
consumption. The plasma of rats orally administered LUT contained free LUT, and the 
conjugation with glucuronide and sulfate of LUT and o-methyl LUT (diosmetin or chrysoeryol). 
The maximum concentrations of LUT can be achieved in 1-2 hours after ingestion, and LUT 
remains in the plasma for several hours before renal excretion as LUT conjugates(8, 49). In 
addition, deglucuronidation of flavonoid glucuronides have been reported to occur in the large 
intestine via bacterial β-glucuronidase, and aryl sulfatase. Plasma concentrations of luteolin 
aglycone can be increased in some pathological processes such as inflammation according to 
deglucuronidation of LUT monoglucuronide by stimulated neutrophils or certain injured cells 
during this physiological condition(50). 
In terms of toxicity, LUT has LD50 values of 411 mg/kg intraperitoneal injection in rats 
and more than 180 mg/kg in mice. Oral administration in mice was determined with LD50 value 
more than 2500 mg/kg (49). 
LUT has been shown to possess a wide range of biological activities such as antioxidant, 
anti-inflammatory, and anticancer activities. In comparison to the glycosides, LUT aglycone was 
more effective according to the absorption rate. 
Antioxidant properties of flavonoids are widely acknowledged from their structures. LUT 
has a catechol group on B-ring and the presence of a C2-C3 double bond in conjugation with an 
oxo group at C4 on the C-ring, which serve to donate hydrogen or electron to stabilize a radical 
species, as well as to bind transition metal ions such as iron and copper. Besides, LUT can 
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penetrate into the nuclei and reduce DNA damage induced by oxidative stress. In cell culture 
studies, malondialdehyde production stimulated by tert-butyl hydroperoxide was reduced with 
LUT treatment which its antioxidant potential was achieved through Nrf2/MAPK mediated HO-1 
signaling cascade in RAW 264.7 cells (7). 
LUT and its glycosides, as well as plants containing LUT have been shown to have anti-
inflammatory properties both in vitro and in vivo. Similar to their antioxidant properties, the 
anti-inflammatory properties also associate with the ortho-dihydroxy groups at the B-ring and 
OH substitution at C5 position on the A-ring (51). These compounds work by inhibiting activation 
of NF-B and AP-1 transcription factors through different phosphorylation cascades proteins 
and inflammatory cytokines, and result in downregulation of downstream proteins such as iNOS, 
COX-2, and lipoxygenase (LOX). In LPS-induced murine macrophage, LUT inhibited Akt 
phosphorylation, NF-B mediated gene expression, and the release of inflammatory cytokines 
including TNF-α and IL-6. LUT also exerts its anti-inflammatory effects by blocking the activity of 
HSP90 in macrophages (52). In animal studies, LUT inhibited arachidonic- or 12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced ear edema (53). Pre-treatment with LUT oral 
application also increased survival rate of mice being challenged with LPS by decreasing TNF-α 
production, ICAM-1 expression in the liver and abolished leukocyte infiltration in the liver and 
lung (8, 49). LUT can trigger changes of transcriptome in microglial cells under both conditions 
with and without LPS, suggesting that it could be a promising agent to develop immuno-
modulatory and neuroprotective therapies for disorders relating to inflammation (54). These 
anti-inflammatory properties of LUT may play important roles in cancer preventive activity of 
this flavonoid. 
Regarding cancer chemopreventive potential, topical application of LUT reduced tumor 
incidence and multiplicity in either TPA or 7,12-dimethylbenzanthracene-induced skin 
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papillomas in mice. Extract containing LUT in the drinking water enhanced a reduction in tumor 
volume although no significant change in tumor incidence or multiplicity was observed. LUT, its 
glycosides, and extracts containing these compounds demonstrated radioprotective effects by 
reducing ROS and suppressing lipid oxidation. Several mechanisms have been revealed in the 
cancer chemopreventive activity of LUT including inhibition of angiogenesis via inhibition of the 
phosphatidylinositol 3'-kinase (PI3K) pathway in a murine xenograft model with VEGF-induced 
angiogenesis. LUT can decrease the incidence of invasion and metastasis by inhibiting MMPs. 
LUT can induce apoptosis in several cancer cell lines but not in normal human peripheral blood 
mononuclear cells. Its anti-apoptosis has been associated with the ability to induce activation of 
p53, to imbalance the Bcl-2 family of proteins, to promote STAT3 degradation by binding with 
HSP90, and to inhibit fatty acid synthase activity. In addition, LUT significantly sensitized TNF-
induced cell apoptosis via ROS accumulation which results in inhibiting NF-B and increasing 
activation of JNK (8, 9).   
2.3.1.3 Curcumin 
Curcumin (CUR) or diferoylmethane is a polyphenol. It is a principal curcuminoid derived 
from the rhizome of turmeric (Curcuma longa). It is soluble in acetone, dimethyl sulfoxide 
(DMSO), or ethanol but not well soluble in water. CUR can exist in both bis-keto and enol forms. 
The keto form, that acts as an H-atom donor, predominates in solid state as well as in acidic and 
neutral solutions while the enol form predominates under alkaline conditions. CUR has 
demonstrated ranges of therapeutic effects including antioxidant, anti-inflammatory and 
anticancer properties. These activities are attributed to the chemistry of CUR molecule that 
contains double conjugated bond in the side chain, two methoxy groups, two phenolic hydroxyl 
groups, and central β-diketone moiety. 
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Products from turmeric have been considered as safe by Food and Drug Administration 
(FDA) in the USA, and Agricultural Organization/World Health Organization (FAO/WHO).  A 
clinical study showed that oral CUR consumption had no toxicity at a dose of 8 g/day for up to 
18 months. However, the results could vary depending on the individual. Another study in 
healthy volunteers orally intake 500-12,000 mg CUR showed that 7 out of 24 subjects developed 
adverse effects including diarrhea, headaches, rashes, and yellowish stools. All toxicities were 
grade 1 and no correlation with doses were observed.  
CUR has low bioavailability in human due to its instability, low solubility, low absorption, 
rapid metabolism through conjugation, and rapid elimination. In solution, CUR was found 
degraded within 30 minutes to trans-6-(4’-hydroxy-3’-methoxyphenyl)-2,4-dioxo-5-hexanal, 
vanillin, feruloylmethane, and ferulic acid. Corresponding to the poor absorption of the 
molecule, low levels of CUR were found in plasma. A study in patients with pre-invasive 
malignant or high-risk premalignant conditions showed that high dose daily CUR consumption 
(8,000 mg) for three months provided a peak serum CUR as 1.75 µM in 1-2 hours after oral 
intake and the level gradually declined in 12 hours. Majority of CUR oral consumption was 
excreted in feces with 35% unchanged form, and the remaining 65% as CUR metabolites. In the 
case of intravenous, and intraperitoneal administration of CUR in rats and mice, the 
metabolites, mainly dihydrocurcumin, tetrahydrocurcumin, and hexahydrocurcumin were 
derived from CUR before being converted to monoglucuronide conjugates, which were found 
excreted in bile (55-58). A study of CUR metabolism from human and rat intestinal and hepatic 
subcellular fraction demonstrated different results between the species. The extent of CUR 
conjugation with sulfate and/or glucuronide was more in the intestinal fractions from humans 
than those from rats, while the conjugation was less extensive in the liver fractions from 
humans than those from rats (59).  
 37 
CUR can improve rheumatoid arthritis, psoriasis, inflammatory bowel disease, 
postoperative inflammation, and inflammatory pseudo-tumors. The anti-inflammatory targets 
of CUR include NOS, COX-2, chemokines, and pro-inflammatory cytokines such as IL-1, IL-2, IL-6, 
IL-8, IL-12, and TNF-α, most likely through inactivation of the transcription factors, NF-B, and 
AP-1, and p38 mitogen activated protein kinase (MAPK) depending on inflammatory inducers 
and cell types (24, 56, 57). 
Antioxidant properties of CUR are supported by its ability to directly scavenge ROS, as 
well as the evidence that it increased in PPAR, GSH, HO-1, SOD, but it decreased ROS, and 
inhibited LDL oxidation (56, 57). These properties are dependent on CUR concentrations and 
chemical environments such as an availability of free Cu2+ ions. High concentrations of CUR were 
shown to increase cellular ROS, which is one of the anti-proliferative mechanisms in cancer (55). 
The anticancer properties of CUR have been demonstrated through the efficacy of the 
molecule that can suppress proliferation, induce apoptosis in different cancer cell lines and 
inhibit tumor formation in animal models of carcinogenesis. CUR multi-targets different 
biological molecules including growth factors, cell receptors, transcription factors, and signaling 
molecules in different pathways. For example, COX-2, EGFR, ERK1/2 and constitutively active 
NF-B and IB kinase in pancreatic cancer were down-regulated by CUR. In vivo anticancer 
properties confirm the in vitro studies. Intravenous administration of CUR liposome reduced 
tumor size and decreased protein expression of CD31, VEGF, and IL-8 in murine xenograft 
model. In many cases, CUR kills tumor cells without adverse effects on normal cells (55). In 
azoxymethane-induced rat’s adenocarcinoma model, CUR orally fed by mixing with diet, dose 
dependently inhibited the disease during tumor initiation, post-initiation and throughout the 
promotion/progression stages by increasing apoptosis in the colon tumors (10).  
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2.3.2 Combination of Dietary Bioactive Components as a Strategic Solution 
Accumulating evidence suggests chemopreventive properties of dietary bioactive 
components as well as other biological activities that they possess. Phytochemicals from foods 
have received attention to prevent cancer and other diseases due to their few or no adverse 
effects that are frequently found after long-term administration of pharmaceutical drugs (2). 
Recently, studies have demonstrated specific combinations of phytochemicals that enhanced 
biological activities more than using a single compound purified from fruits and vegetables 
(Table 2.3). In fact, phytochemicals have also been combined with drugs to reduce drug toxicity 
and enhance efficacy of treatments. Using multiple compounds in combinations could provide 
antioxidative, anti-inflammatory, and chemopreventive improvements because different 
compounds may target through different mechanistic pathways and offer a better result than 
using one compound. This could lead to lower doses requirement thus reducing side effects and 
minimizing the development of drug resistance (3).  
ITCs, not only as a single treatment, but also as a co-treatment with other bioactive 
compounds, have wide range of biological activities including anticancer, anti-inflammation and 
antioxidant. In table 2.3, some studies emphasize enhanced biological activities when using 
dietary bioactive components in combinations. Shen et al.(60) used the Apc Min/+ mouse model 
to investigate a combination of SFN and dibenzoylmethane (DBM), an aromatic compound 
found in licorice. In this experimental model, mice have a hereditary disease with an inactivation 
of one allele of the adenomatous polyposis coli gene and prone to having multiple polyps in 
their colon. Without removal, these polyps may eventually progress to colon cancer. The 
combination treatment blocked the colon tumor development, while SFN and DBM alone 
reduced tumor number by 80% and 60%, respectively. No statistical difference in the levels of 
inflammatory mediators were found between tumor samples treated with the combination 
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Table 2.3 The effects of the combination of phytochemicals 
Compounds in 
combination 
Model of study Effect Reference 
Sulforaphane and 
Dibenzoylmethane 
APCMin/+ mice - Anti-tumor development with 
significantly reduced number of 
tumors 
(60) 
Sulforaphane and 
3,3’-
Diindoylmethane 
HCT116 colon cancer 
cells 
 
- Anti-proliferation 
- Increase of G2/M phase 
cell cycle arrest 
(61) 
Sulforaphane and 
Apigenin 
Caco-2 colon cancer 
cells 
- Induction of phase 2 detoxification 
enzyme, UDP-
glucuronosyltransferase (UGT1A1) 
(62) 
Sulforaphane and 
Nobiletin  
RAW 264.7 
macrophages 
- Anti-inflammation  
- Decrease of iNOS and COX-2 
expression 
- Induction of HO-1 expression 
(63) 
Sulforaphane and 
Curcumin 
 
Sulforaphane and 
Phenethyl 
isothiocyanate 
RAW 264.7 
macrophages 
- Anti-inflammation 
- Reduction of inflammatory markers 
including iNOS, COX-2, PGE2, 
TNF, and IL-1 
- Induction of phase 2 enzymes such 
as HO-1, and NQO-1 
(64) 
Luteolin and 
Celecoxib  
MCF-7 and MDA-MB-
231 breast cancer 
cells 
- Anti-proliferation 
- Increase of apoptotic cells 
- Decrease of Akt phosphorylation 
(65) 
Luteolin and 
Chicoric acid 
RAW 264.7 
macrophages 
- Anti-inflammation 
- Reduction of inflammatory markers 
including NO, PGE2, iNOS,COX-2, 
TNF-α, and IL-1β through 
phosphorylation of NF-B and Akt 
(66) 
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Table 2.3 (Continued) The effects of the combination of phytochemicals 
Compounds in 
combination 
Model of study Effect Reference 
Luteolin and 
Tangeritin 
RAW 264.7 
macrophages 
- Anti-inflammation 
- Reduction of inflammatory markers 
including NO, PGE2, iNOS,COX-2, 
IL-6, and IL-1β 
(67) 
Curcumin and 
piperine 
Oral administration in 
rats and human 
 
Patients with tropical 
pancreatitis 
- Increase of CUR bioavailability 
without adverse effects 
- Antioxidant properties by 
decreasing MDA levels and 
increasing GSH levels in 
erythrocytes 
 
(68) 
 
 
(69) 
Curcumin and 
Quercetin 
Patients with familial 
adenomatous 
polyposis 
- Decrease of number and 
size of polyps without 
appreciable toxicity 
(70) 
Curcumin and 
Phenethyl 
isothiocyanate 
Human PC-3 prostate 
xenografts in 
immunodeficient mice 
- Reduction of the growth of PC-3 
xenografts 
- Inhibition of cell proliferation and 
induction of apoptosis through 
inhibition of Akt and nuclear factor-
κB signaling pathways 
(71) 
 
Curcumin and 
Polyunsaturated 
fatty acids 
RAW 264.7 
macrophages 
- Anti-inflammation 
- Reduction of inflammatory markers 
including NO, PGE2, iNOS,COX-2, 
5-LOX, and cPLA2  
- Increase of an antioxidant enzyme, 
HO-1 
(72) 
 
 
and the samples treated with individual component. However, both SFN and DBM alone as well 
as their combination significantly decreased PGE2, leukotrieneB4, and expression of protein 
markers of cell proliferation, suggesting both of them as potent dietary compounds for 
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chemoprevention of gastrointestinal cancers. Another study using colon cancer cells also 
demonstrated a synergy from using combination treatment. Pappa et al.(61) reported that the 
incorporation of two glucosinolate products, sulforaphane and 3,3’-diindoylmethane, in HCT116 
cells dose-dependently provided synergistic anti-cell proliferation by arresting cell cycle at G2/M 
phase. At low doses, antagonism was observed, which was possibly due to low SFN doses (1-5 
µM) that were very effective in inducing cell protective phase 2 detoxification enzymes. 
Therefore, we should be aware of doses of utilization to avoid undesirable effects. Besides 
inhibition of cancer cell and tumor growth, a combination treatment between SFN and apigenin 
provided a synergistic induction of phase 2 detoxification enzyme UDP-glucuronosyltransferase 
(UGT1A1) for cancer prevention. The synergy from apigenin and SFN was possibly due to 
complementary effects from different mechanisms associating with NF-B translocation of the 
two compounds (62). In addition, synergistic anti-inflammatory effects were also demonstrated 
in the combined treatments between SFN and nobiletin (63), SFN and curcumin, and SFN and 
phenethyl isothiocyanate (PEITC) (64). The combinatorial treatments decreased the release of 
pro-inflammatory mediators (NO, PGE2, TNF, and IL-1), and the expression of inflammatory 
proteins (iNOS, and COX-2), as well as increased the expression of phase 2 antioxidant enzymes 
(HO-1 and NQO-1). 
Besides the aforementioned studies on the combination of ITCs with some 
phytochemicals, in vitro studies have exhibited the synergism between LUT and some other 
compounds. In combination with celecoxib, LUT synergistically increased apoptosis in breast 
cancer cells, especially in MDA-MB-231 cells, in which the combined treatment increased 50% 
apoptotic cells in comparison to control after 72-hour treatment. The combined treatment also 
decreased expression level of phosphorylated Akt, in which its activation plays a regulatory role 
in pro-oncogenic pathways (65). LUT and chicoric acid in combination synergistically reduced 
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inflammation in LPS-induced RAW 264.7 cells by decreasing cellular concentration of pro-
inflammatory cytokines (TNF-α, and IL-1β), NO, PGE2, and inhibiting expression of iNOS and 
COX-2. These anti-inflammatory potencies were regulated through the decreased level of 
phosphorylated NF-B and the phosphorylated Akt  (66). In addition, synergistic anti-
inflammation of LUT was observed when it was combined with tangeritin (67). This combination 
decreased the level of NO, PGE2, IL-1β, and IL-6 released by LPS-activated RAW 264.7 cells. The 
combined treatment also decreased mRNA and protein expression levels of iNOS and COX-2. 
Some of the combinations such as CUR co-administered with piperine, which is an 
alkaloid found in black pepper, orally administered in rats and healthy human volunteers 
suggest an increase of bioavailability as much as 154%, and 2000%, respectively with no adverse 
effect. The combination increased the serum concentration of CUR after ingestion, and 
decreased CUR elimination (68). In addition, 500mg of CUR with 5mg of piperine enhanced 
antioxidant activities in patients with tropical pancreatitis by reducing in the erythrocyte MDA 
levels and increasing GSH levels although there was no corresponding improvement in pain (69). 
Three times a day treatment of the combination of CUR and quercetin for 6 months significantly 
decreased number and size of ileal and rectal adenomas in all 5 patients with familial 
adenomatous polyposis without producing any appreciable toxicity (70). In immunodeficient 
mice grafted with human PC-3 prostate, the combination of CUR with PEITC significantly 
inhibited the growth of xenografts while the single treatment of PEITC and curcumin failed to 
affect the growth of prostate tumor xenografts. The combined treatment increased apoptosis by 
responding through caspase-3 and PARP. Reduced protein expression of p-Akt, p-GSK3βα, p-
BAD, p-IKKβα, and p-IκBα were closely correlated with the reduction of PC-3 tumor xenografts, 
suggesting mechanistic pathways that CUR and PEITC are involved (71). In addition to the 
anticancer and antioxidant properties, CUR combination with polyunsaturated fatty acids 
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(docosahexaenoic acid or eicosapentaenoic acid) provided synergistic anti-inflammation in LPS-
induced RAW 264.7 cells by decreasing NO, PGE2, as well as the proteins and mRNA levels of 
iNOS, COX-2, 5-LOX, and cytosolic phospholipase A2 (cPLA2), and increasing HO-1 (72).  
However, combination treatment does not only provide beneficial enhanced 
therapeutic efficacies. Some adverse effects have been noted. For example, co-administration of 
CUR and nonsteroidal anti-inflammatory drugs or anti-coagulant drugs may result in an increase 
risks of bleeding (57). 
A growing number of both in vivo and in vitro studies support enhanced biological 
activities of combinations of dietary bioactives over a single compound utilization. Many of 
them synergistically act together, suggesting why some foods demonstrate cancer 
chemopreventive properties which cannot be explained based on an individual bioactive 
ingredient. In fact, it is critical to understand how phytochemicals provide synergistic effects in 
terms of both chemistry and biology. Therefore, further exploration of the mechanisms of action 
would increase beneficial and reliable outcomes for the development of supplement regimens, 
cancer prevention and therapies (41). 
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CHAPTER 3 
 
SYNERGISTIC CHEMOPREVENTIVE EFFECT OF ALLYL ISOTHIOCYANATE AND SULFORAPHANE 
ON A549 NON-SMALL CELL LUNG CARCINOMA CELLS 
 
3.1 Introduction 
Lung cancer is one of the most common cancers. Although the rate of incidence and 
death from lung and bronchus cancer has decreased in the past few decades, this type of cancer 
had been estimated to be the number one cause of cancer death thus it is still a major health 
problem in many parts of the world (73). Accumulating evidence suggests therapeutics based on 
mechanisms of actions of cancers to appropriately control specific targets such as targeting 
cancer stem cells, microenvironment, mutant kinases, etc (74, 75). However, there is another 
strategy known as chemoprevention that could be effective to prevent cancer from being 
initiated, promoted and/or progressed to the advanced malignant stages. Among 
chemopreventive agents, natural compounds from fruits and vegetables are of interest due to 
their multi-targeting activities, low toxicity, and low cost (76).  
Isothiocyanates (ITCs) are well-known naturally occurring small molecules that are 
produced by enzymatic conversion of glucosinolate precursors in cruciferous vegetables. ITCs 
are suggested to be promising anticancer agents. Many of them including allyl isothiocyanate 
(AIT) and sulforaphane (SFN) displayed anticarcinogenic activity through various mechanisms 
including reducing activation of carcinogens, reducing cancer cell proliferation, inducing cell 
cycle arrest leading to apoptosis, and decreasing invasion and metastasis (4, 5). 
Combination of cancer chemopreventive agents is an alternative strategy that at least  
two compounds may effectively act against cancer growth by synergistic type of interaction and 
result in stronger effects compared to the result obtained by each compound individually (2). 
Using multiple compounds in combinations could provide chemopreventive improvements and 
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target through different mechanistic pathways offering a better result than using one 
compound. This could lead to lower dose requirement thus reducing side effects and minimizing 
the development of drug resistance (3). Several ITCs combinations have been tested on 
different cancers by combining among themselves or with other anticancer agents, and 
synergies have been observed on the basis of the combination index (CI) or relevant statistical 
analyses (3).  Gupta et al.(5) demonstrated that either benzyl- or phenyl ITCs can sensitize 
platinum containing agents in lung cancer.  However, the combined effects of ITCs, especially 
AIT and SFN on carcinogenesis have not been well studied. Herein, we tested the hypothesis 
that the combination of AIT and SFN produce a synergy in inhibiting the growth of human non-
small cell lung cancer cells (A549).  Therefore, we examined the effect of AIT and SFN 
administered to cells individually in comparison to the mixture of them on cell survival and cell 
migration. To determine pathways underlying the mechanisms of the combined treatment, we 
investigated expression of protein markers associated with apoptosis, cell cycle arrest, cell 
invasion and metastasis. We found significantly higher anticancer effects from using AIT-SFN in 
combination rather than the individual compound against lung carcinogenesis. 
3.2 Materials and Methods 
3.2.1 Cells Culture and Treatments 
Lung cancer A549 cells were purchased from American Type Culture Collection (ATCC, 
Rockville, MD, USA), and were cultured in RPMI-1640 medium supplemented with 5% heat-
inactivated fetal bovine serum (FBS) and 100U/ml of penicillin and 0.1 mg/ml of streptomycin at 
37°C with 5% CO2. Dimethyl sulfoxide (DMSO) at final concentration of 0.1 % v/v was used to 
prepare cell treatments which are 2.5 - 12.5 µM AIT (98%, Sigma-Aldrich, St. Louis, MO, USA), 
and 2 - 10 µM SFN (> 98 %, Qualityphytochemicals, Edison, NJ, USA). Cells were treated with 
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freshly prepared treatment in culture medium for 72 hours before subjecting to further analysis 
as described below. 
3.2.2 Measurement of Cell Viability 
Cytotoxicity of AIT and SFN treatments on A549 cells were assessed by the enzymatic 
reduction of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT; Sigma-
Aldrich) as previously described (77) . Briefly, 2000 cells/well grown in 96-well tissue culture 
plates were exposed to indicated series concentrations of AIT and SFN.  After treatment, cells 
were incubated for 1 hour with 0.5 mg/ml of MTT solution in cell culture medium and the 
absorbance of resulting formazan product was measured at 570 nm using a microplate reader 
(SpectraMax, Molecular Devices, Sunnyvale, CA, USA).  
 
3.2.3 Detection of Apoptosis 
Treated cells (4 x 104 cells/well in a 6-well plate) were washed with iced-cold phosphate 
buffer saline (PBS) and detached using trypsin (0.25% trypsin-EDTA; Mediatech, Manassas, VA, 
USA). Analysis of apoptosis by flow-cytometry (BD LSRII, BD Biosciences, San Jose, CA, USA) was 
accessed using dual staining, Annexin V fluorescein isothiocyanate (Annexin V-FITC) and 
propidium iodide (PI) in Annexin V binding buffer (BioVision, Milpitas, CA, USA) as previously 
described (78). Annexin V-positive/PI-negative cells were identified as they are in early stage 
apoptosis, while late apoptosis contains Annexin V-positive/PI-positive cells. 
 
3.2.4 Cell-Cycle Analysis 
Collected cells were fixed in 70% ethanol overnight at 4 °C.  As previously described 
(78), cells were suspended in PBS containing PI, and RNase (Sigma-Aldrich) in the dark for 30 
minutes and analyzed on a flow cytometer. The population of cells in each cell-cycle phase was 
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determined using BD LSRII flow cytometer (BD Biosciences), and data were processed using 
ModFit LT software. 
 
3.2.5 Examination of Intracellular ROS Accumulation 
ROS in cells were monitored by a modified method from Wang et al.(79). Cells were 
stained with 10 M 2, 7-dichlorodihydrofluorescein diacetate (DCFH-DA; Sigma-Aldrich) in the 
dark for 30 minutes followed by fluorescent detection using flow-cytometry. Fluorescent 
intensity of DCFH dye uptaked relatively reflected intracellular ROS levels.  
3.2.6 Cell Migration Assay 
A wound healing assay adapted from Zhou et al.(80)  was performed to observe cancer 
cell migration. A549 (1.0×105 cells) were seeded in 24-well plate and were allowed to grow to a 
confluent monolayer. Prior to scratch using a 200 µL- pipette tip, cells were washed with cold 
PBS. Medium containing treatment was added to each well followed by gap-width 
measurement using a transparent microscope (Eclipse TS100, Nikon, Melville, NY, USA) at the 
beginning and the end of treatment (72 hours). For visual enhancement, cells were dyed with 
crystal violet at the end of the treatment. Percent change in wound width reflected percent cells 
migration. 
 
3.2.7 Western Blotting 
Whole cell lysates were prepared as previously described (78). Attached cells on the 
culture plates were washed with cold PBS prior to the addition of RIPA buffer containing 
protease and phosphatase inhibitors (Boston BioProducts, Ashland, MA, USA). Cells were 
collected using cell scrapers into Eppendorf tubes and were placed on ice for 20 minutes. Cell 
suspensions were then sonicated and lysed on ice for a further 20 minutes. Supernatants were 
collected after centrifugation at 20,817 x g for 10 minutes and used to determine protein 
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concentrations by bicinchoninic acid (BCA) protein assay. Equal amounts of proteins were 
resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose 
membranes (GVS Filter Technology, Indianapolis, IN). Blocking buffer in PBS was used to block 
non-specific binding of antibodies prior to immunodetection using specific antibodies at the 
manufacturer’s recommended concentrations.  Protein bands were visualized on blots probing 
with secondary antibodies using Odyssey system (LI-COR, Lincoln, NE, USA). Antibodies for 
cleaved caspaes-3, caspase-3, cleaved PARP, PARP, Survivin, Bcl-xL, Cyclin B1, p21, STAT3 and 
MMP-9 were obtained from Cell Signaling Technology (Danvers, MA, USA). Antibodies for p53, 
COX-2, and p-STAT3 were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). -Actin 
antibody obtained from Sigma-Aldrich (St. Louis, MO, USA) was used as a loading control. 
 
3.2.8 Analyses of Synergy  
Synergistic effects of AIT-SFN combinations were analyzed based on Chou and Talalay’s 
method (3) with modifications using R software. This model is used for constant ratio drug 
combinations. When the combination dose of d1 and d2 provides the same effect x as Drug1 
alone at dose Dx,1 and Drug2 alone at dose Dx,2, the combination index (equation 1) indicates 
synergism, additivity, or antagonism of the combinatorial effect when the index <1, =1, or >1, 
respectively.  
Combination index = d1/Dx,1+ d2/Dx,2          (1)  
The median-effect plot demonstrated by the equation 2 was used to find D value which 
is the dose of a test compound that demonstrates the E effect. E is the fraction of cell survival in 
this study while α is a slope parameter, and Dm presents the median effective dose of the 
compound. 
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log [E/(1-E)] = α(log D + log Dm)     (2) 
 
3.2.9 Correlation Analysis 
Pearson correlation analysis was performed to investigate the association between 
different factors on the inhibition of cell proliferation related to oxidative stress after being 
exposed to treatments. Correlations were considered significant when P value is less than 0.05. 
3.2.10 Statistical Analysis 
All cell culture experiments were repeated for at least three times with similar results .
Statistical comparisons were made using one-way analysis of variance (ANOVA) and P value of 
less than 0.05 was considered significant. 
3.3 Results 
3.3.1 AIT-SFN Synergistically Reduced A549 Cell Viability 
Using MTT assay, the effect of single compound of AIT and SFN on A549 lung cancer cell 
viability was determined in comparison to their combined treatment with a constant ratio of 
AIT:SFN at 1.25:1 based on their IC50 values which were 12.6 ± 1.2, and 10.3 ± 0.6 µM, 
respectively. Figure 3.1A shows a concentration-dependent efficacy of both single and combined 
treatments that they decreased cell viability after 72 hours. AIT (2.5 - 12.5 M) or SFN (2 - 10 
M) alone decreased cell proliferation from 3.2% to 50.9% and from 4.2% to 49.9%, 
respectively. Utilization of AIT and SFN co-treatment provided stronger anti-proliferation than 
that of a single treatment, which is reflected by fewer viable cells and less concentration 
requirement. Half-dose combination between AIT and SFN (6.25 M AIT with 5 M SFN) 
provided as high as 58.6 % inhibition of cell viability. Based on Chou and Talalay’s method (3), 
we further determined the mode of interaction between the two compounds by median-effect 
plot and isobologram analyses. The median effect plot (Figure 3.1B) demonstrated reduced IC50  
 50 
 
 
Figure 3.1 Growth inhibitory effects of AIT, SFN, and their combined treatment on non-small 
cell lung cancer A549. Cells were treated for 72 hours before viability measurement by MTT 
assay. Data are shown as mean ± SD (n = 6). Combination indexes are shown in parentheses (A). 
Median-effect plot (B) and isobologram analyses (C) of synergy between the combination of AIT 
and SFN at different concentrations (1.25 µM AIT + 1 µM SFN, 2.5 µM LUT + 2 µM SFN, 3.75 µM 
AIT + 3 µM SFN, 5 µM AIT + 4 µM SFN, and 6.25 µM AIT + 5 µM SFN) with in the ratio of 1.25:1 
were constructed using Chou and Talalay’s method (3). 
 
values of the combined treatments (5.53 ± 0.31 µM AIT and 4.43 ± 0.24 µM SFN) in comparison 
to the IC50 values of each compound. Isobologram (Figure 3.1C) confirmed the synergistic effect 
from the combined treatment with the combination index ranging from 0.82 – 0.94 (Figure 
3.1A). 
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3.3.2 AIT-SFN Synergistically Induced Cellular Apoptosis 
Early and late apoptotic cells were relatively quantified by flow cytometry with Annexin 
V/PI co-staining after 72-hour treatment. Figure 3.2A which are representative images of 
Annexin-V/PI intensity dot plots of A549 cells, showed significantly increased dot intensity in Q2 
(late apoptosis) and Q4 (early apoptosis) region and decreased dot intensity in Q3 region (non-
apoptotic cells) in the AIT-SFN combined treatment group. Percent apoptotic cells were 
obtained from the Annexin-V/PI dot plots. As shown in figure 3.2B, numbers of both early and 
late apoptotic cells increased in dose-dependent manner under single and combined 
treatments. Single treatment of AIT (12.5 µM) significantly increased numbers of early apoptotic 
cells (8%) in comparison to control while the single treatment of SFN (10 µM) significantly 
increased numbers of both early and late apoptotic cells by 8, and 13%, respectively. 
Combination treatment, especially at higher concentrations clearly increased numbers of cells in 
late-stage apoptosis over those in early-stage apoptosis. The increment of early apoptotic cells 
under combination treatment stopped after reaching 15% as the highest concentrations of the 
combined treatment did not increase apoptotic cells in comparison to the milder combined 
treatments. However, the number of late apoptotic cells as well as total apoptotic cells under 
the combination treatments were dose-dependent. A synergy in total apoptosis (CI = 0.61-0.79) 
was observed at as low doses as 6.25 M AIT with 5 M SFN that could increase 34% total 
apoptotic cells. The higher combined doses (12.5 M AIT with 10 M SFN) increased more 
apoptotic cells to 52% in total in comparison to control without treatment.  
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Figure 3.2 Effect of AIT, SFN, and their combination on apoptosis. Cells were treated for 72 
hours, followed by apoptosis measurement with flow cytometry after Annexin-V/PI co-staining. 
(A) Representative images of Annexin-V/PI intensity dot plots of A549 cells showed significantly 
increased dot intensity in Q2 (late apoptosis) and Q4 (early apoptosis) region and decreased dot 
intensity in Q3 region (non-apoptotic cells) in the AIT-SFN combined treatment group. (B) 
Percent apoptotic cells were calculated from the Annexin-V/PI dot plots. Results are presented 
as mean ± SD (n = 3; *P < 0.05). Combination index (CI) ± SE are in parentheses. (C) Expression of 
relating proteins were monitored by Western Blotting. The protein band intensities underneath 
the blots were quantified using Image Studio software. β-Actin served as an internal loading 
control. The results are representative of 3 experiments. 
Q1 Q2 
Q3 Q4 
Q1 
Q1 Q1 
Q2 
Q2 Q2 
Q3 
Q3 Q3 
Q4 
Q4 Q4 
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To further elucidate the molecular basis for this event, expression of proteins associated with 
apoptosis pathways was compared through immunoblotting. As shown in Figure 3.2C, both 
single and combined treatment dose-dependently decreased expression of survivin, an anti-
apoptotic protein, and increased expression level of pro-apoptotic proteins which are p53, 
cleaved caspase-3, and cleaved PARP. The highest concentrations of the combined treatment at 
12.5 M AIT with 10 M SFN, obviously increased expression of pro-apoptotic proteins, 
especially cleaved PARP that were 70.5-fold increased while the expression of PARP did not 
change much, suggesting the abundance of PARP in cells. The expression of cleaved caspase-3 
was 6.5-fold increased with a correspondingly decreased of the expression of caspase-3 at the 
highest combinatorial concentration, suggesting a conversion of caspase-3 to cleaved caspase-3. 
In addition, Bcl-xL which is a member of Bcl-2 family known as an anti-apoptotic regulator also 
had relatively constant expression under treatments compared to the control. The results of 
pro- and anti-apoptotic proteins expression were consistent with Annexin V/PI co-staining 
analysis that demonstrates enhanced apoptotic effects from the combined treatment. The 
results suggested that the combination of AIT and SFN improved the anti-proliferation of A549 
lung cancer cells through increasing number of apoptotic cells, especially at the late-stage 
apoptosis. 
3.3.3 AIT-SFN Significantly Induced G2/M Cell Cycle Arrest   
To gain further insight into the mechanism of their anti-proliferative activities, A549 
cells were treated with either AIT (3.125, 6.25, 12.5 μM), or SFN (2.5, 5, 10 μM) alone or in 
combination, and their effect on cell cycle progression and distributions were assessed after 72-
hour treatment. In figure 3.3A, representative images of A549 cell cycle histogram showed 
significantly increased G2/M phase arrest in the AIT-SFN combined treatment group. Percent 
cells population in each phase were calculated from the cell cycle histogram. As shown in Figure 
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3.3B, in comparison to control, there was no major phase-specific change in cell-cycle 
progression under any single treatment at the concentrations lower than 12.5 μM and 10 μM 
for AIT, and SFN, respectively. At these high concentrations, AIT decreased G0/G1 cell 
population but did not significantly change cell population of the other phases while SFN  
 
 
 
Figure 3.3 Effect of AIT, SFN, and their combination on cell cycle after 72-hour treatments. Cells 
were fixed with ethanol, treated with RNAse and PI before determining cell cycle progression by 
flow cytometry. (A) Representative images of A549 cell cycle histogram showed significantly 
increased G2/M phase arrest in the AIT-SFN combined treatment group. (B) Percent cells population 
in each phase were calculated from the cell cycle histogram. Results are presented as mean ± SD (n 
= 3; *P < 0.05). (C) Expression of cyclin B1 and p21 which relates to G2/M phase arrest were 
determined using Western Blotting. The protein band intensities underneath the blots were 
quantified using Image Studio software. β-Actin served as an internal loading control. 
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significantly increased G2/M phase arrest with a decrease in S-phase population. AIT and SFN 
combined treatment at concentrations of 12.5 and 10 μM, respectively significantly increased 
G2/M phase arrest with up to 47% and lowered G0/G1 population to 37%. However, the 
combination treatment under the concentration used in this study did not show any synergy on 
G2/M phase arrest of A549 cell population. Although there was no synergy from the combined 
treatment on the result of cell cycle arrest, protein expression of p21 (Figure 3.3C) which is a 
G2/M phase negative regulator was increased in dose-dependent pattern with the maximum at 
5-fold under high-dose combined treatment (12.5 μM AIT with 10 μM SFN). An opposite trend 
was observed in the expression of cyclin B1, which is necessary during G2/M phase of cell cycle. 
Decreased expression of this protein (9-fold lower than control) increased G2/M phase of cell 
arrest. The results of protein expression corresponded to the flow cytometry analysis of PI-
stained cells that combination treatment of AIT and SFN increased G2/M phase arrest in A549 
cells. 
3.3.4 AIT-SFN Significantly Increased Cellular Oxidative Stress 
Cellular oxidative stress, was assayed in DCFH-DA-stainned A549 cells after 72-hour 
treatment using flow cytometry (Figure 3.4). ROS was monitored only in the population of lived-
cells due to non-stainable property of dead cells. There was a significant increase of ROS levels 
in A549 treated with combined treatment. The concentrations of 6.25 M AIT with 5 M SFN, 
and 12.5 M AIT with 10 M SFN increased ROS 1.9-, and 2.9-fold, respectively. Combined 
treatment at lower concentrations than those indicated doses as well as single treatment (as 
high dose as 12.5 M AIT or 10 M SFN) did not significantly change ROS in A549 cells in 
comparison to control. 
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Figure 3.4 Effect of AIT, SFN, and their 
combination on cellular ROS. A549 cells 
were incubated with the indicated 
treatments for 72 hours and stained with 
DCFH-DA before detection by flow 
cytometry. Results are presented as mean 
± SD (n = 3; *P < 0.05). 
 
Considering correlation analysis (Table 1) between ROS level in A549 and either 
apoptosis or cell cycle arrest that was constructed based on Pearson correlation, there was a 
significantly strong positive correlation between intracellular ROS and apoptosis, especially the 
late apoptosis as well as a correlation between ROS and G2/M phase cell arrest. Slightly less 
correlation was observed between ROS and early apoptosis. A Negative correlation was found 
between ROS and G0/G1 phase arrest while no significant correlation was observed between 
ROS and S phase of cells. The correlation analysis confirmed the consistency of results and 
suggested that apoptosis and G2/M phase arrest under combined treatment were mediated 
through ROS signaling.  
3.3.5 AIT-SFN Synergistically Inhibited Cell Migration 
The inhibitory effect of AIT and SFN on migration of A549 cells through wound healing 
assay was examined by comparing the wound width right after treatment application in 
comparison to the wound width after 72-hour treatment. Figure 3.5A shows representative 
images taken at hour-0 in comparison to hour-72 using 4× magnification. When A549 cells were 
incubated with AIT and SFN in either single or combined treatment, the cell migration was 
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Table 3.1 Correlation analysis of oxidative stress and apoptosis or cell cycle arrest 
Factor Pearson’s 
correlation 
coefficient 
P value 
early apoptosis 0.795 0.006 
late apoptosis 0.957 < 0.001 
total apoptosis 0.932 < 0.001 
G0/G1 phase -0.757 0.011 
S phase -0.558 0.93 
G2/M phase 0.810 0.004 
 
inhibited in a dose-dependent manner (Figure 3.5B). Treatment of AIT at the concentrations of 
6.25, and 12.5 M significantly decreased wound healing by 13, and 22%, respectively. SFN at 10 
M also significantly decreased wound healing by 26%. Furthermore, the synergy from AIT-SFN 
combined treatment was obtained started at as low dose as 3.125 M AIT with 2.5 M SFN. The 
maximal anti-cell migration effect from the highest combinatorial concentrations (12.5 M AIT 
with 10 M SFN) used in this study was 48% with the interaction index of 0.59.  After studying 
cell migration which is an integral part of metastasis, we further examined expression of 
proteins that play important roles in lung cancer metastasis including COX-2, p-STAT3 and MMP-
9 by Western blotting. Treatment of AIT or SFN alone in A549 cells reduced the expression levels 
of COX-2 and p-STAT3 in a dose-dependent manner as compared to the expression of untreated 
control. Low concentration of SFN at 5 M and its half-dose combination (2.5 M SFN with 
3.125 M AIT) slightly increased MMP-9 expression by 0.5-fold while higher concentrations of 
AIT, SFN, and their combinations provided an opposite effect. The results from Western blotting 
were consistent with that observed from cell migration assay that combination treatment 
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between AIT and SFN, especially at higher concentrations improved anti-metastatic property in 
A549 lung cancer cells. 
Figure 3.5 Effect of AIT, SFN, and their combination on cell migration after 72-hour 
treatments. (A) Representative images taken at hour-0 in comparison to hour-72 using 4×  
magnification showed significant inhibitory wound healing by the combination treatment. (B) 
Percent wound healing was calculated from width of the wound. Results are presented as mean 
± SD (n = 4; *P < 0.05). (C) Expression of proteins related to cell migration were determined 
using Western Blotting. The protein band intensities underneath the blots were quantified using 
Image Studio software. β-Actin served as an internal loading control. 
 
3.4 Discussion 
This study has demonstrated for the first time the synergistic effect of two bioactives, 
ITC type of compounds, which are AIT and SFN on A549 chemopreventive properties. First, we 
determined the anti-proliferative potential of AIT and SFN alone in non-small cell lung cancer 
A549. IC50 values after 72-hour treatment of AIT and SFN were 12.64  1.19, and 10.29  0.66 
µM, respectively, suggesting that SFN slightly had higher efficacy than AIT to inhibit A549 cell 
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growth. Corresponding to our results, SFN also had lower IC50 doses than AIT in inhibiting growth 
of 8226/S myeloma and HepG2 cells after being treated for 3 days (81). In addition, the 
cytotoxic effects of ITCs are selective. AIT and SFN did not demonstrate toxicity in non-malignant 
cells at the concentrations that could inhibit growth of cancers (44, 82). Furthermore, they have 
been shown to possess antioxidant properties in healthy cells by lowering ROS through phase II 
detoxification proteins (83-85). 
Based on the IC50 values of AIT and SFN on A549 growth inhibition, a combination of AIT 
and SFN at ratio of 1.25:1 was used in comparison to the single treatment. Our analysis using 
Chou and Talalay’s model (3) displayed similar degree of synergism with the combination index 
ranging from 0.82 – 0.94 over concentrations varied in this study. Through combination index 
analyses, AIT and SFN combined treatment exhibited synergism by lowering concentrations of 
AIT and SFN 2 - 2.9-fold compared to the results of each compound. This moderate to slight 
interaction is possibly due to characteristics of natural compounds that are multi-targeting but 
milder in comparison to pharmaceutical drugs. Supporting evidence showed that the majority of 
natural compounds in combination provided 2 - 10 fold anticancer improvement (86). As being 
shown in figure 3.1, the mixture of both AIT and SFN present together for 72 hours 
synergistically inhibited growth of A549 cells. On the contrary, the combined treatment with 
one compound presented at a time (either 36-hour AIT followed by 36-hour SFN or SFN followed 
by AIT) did not demonstrate any synergy (data not shown). These data suggested that both 
compounds needed to be applied at the same time to allow enhancement of chemopreventive 
effect of these two ITCs. 
We further demonstrated that the combination of AIT and SFN synergistically increase 
apoptotic cells, particularly in late apoptosis. When comparing the values of combination index 
obtained from cell survival MTT assay and the values obtained from flow cytometric apoptosis 
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assay, we found a stronger synergy from anti-apoptotic activity (CI = 0.61  0.03) in comparison 
to the anti-proliferative activity of A549 cells (CI = 0.82  0.02) using MTT assay. This information 
suggested that AIT and SFN in combination played important roles in controlling cell growth at 
least through apoptosis pathway. However, there are other factors such as cell cycle arrest, 
necrosis, autophagy, as well as phase II detoxification system that might also affect the overall 
efficacy of the treatments on A549 cell survival. The validity of this result was demonstrated by 
Western Blotting, in which treatments clearly increased pro-apoptotic proteins and decreased 
one of the anti-apoptotic proteins expression. A transcription factor, p53,  is known to regulate 
apoptosis upon the increase of its expression through the activation of downstream proteins 
such as caspase-3, PARP, Bcl-xL, and survivin (31). ITCs both single and combined treatments 
dose-dependently increase the expression of p53 and other pro-apoptotic proteins. The increase 
of p53 led to an obvious decrease of the inactive form caspase-3 and to increase expression of 
the active cleaved caspase-3 under combination treatment at high concentrations. PARP which 
had dual role in both DNA repair and apoptosis relatively expressed at constant levels under all 
treatments. Corresponding with the expression of cleaved caspase-3, cleaved PARP was also 
induced by the combination treatment. On the other hand, expression of survivin, an anti-
apoptotic protein inhibiting caspases (87), were decreased, especially by the high-dose 
combination. Although the expression of Bcl-xL remained relatively constant, the overall 
comparative amounts of pro- and anti-apoptotic proteins defined whether the cell will undergo 
cell death. As has been demonstrated here, the expression of three pro-apoptotic proteins were 
increased and one anti-apoptotic proteins was decreased by our treatments. In this case, the 
expression of these pro- and anti-apoptotic proteins corresponded with percent cells in 
apoptosis and suggested that ITC treatments induced apoptosis through p53 transcription factor 
and some of its downstream proteins including cleaved-caspase3, cleaved-PARP, and survivin.  
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Correspondingly, p53 expression not only regulated apoptotic event but also led to an 
effect on cell cycle arrest. The transcription factor p53 could signal growth arrest of cell at a 
checkpoint to allow DNA damage to be repaired before DNA replication or to lead cell arrest 
before entering mitosis and undergo apoptosis when the damage was irreparable (31, 32). Our 
results demonstrated a trend of cells in G2/M phase increase under both single and combined 
treatments upon dose increment, particularly the high-dose combination that significantly 
increased cells in G2/M phase and decreased cells in G0/G1 phase. Although there was no 
synergy obtained on G2/M phase arrest, the data corresponded to the previous experiment that 
the combination of 12.5 µM AIT with 10 µM SFN could synergistically induce apoptosis. Taking 
these data together, the combination treatment once reaching certain concentration at the 
ratio used in this study possibly induced DNA damage as being indicated in several studies(5, 88, 
89), and led to cell cycle arrest at G2/M phase and apoptosis. At the molecular level, this was 
accompanied with the efficient inhibition of the expression of cyclin B1, a regulatory protein in 
mitosis while a protein marker of G1 phase (cyclin D1), and a marker of S phase (cyclin E) were 
increased (data not shown). In addition, p21 which is one of the inhibitors of cyclin-dependent 
kinase that regulates cells mitosis phase, was also increased in expression. 
The increase of intracellular ROS under AIT and SFN combination treatment was 
correlated with cell cycle arrest and apoptosis. Single treatment did not significantly affect the 
ROS level possibly corresponding to their low doses. This information was consistent with other 
studies using SFN and other ITCs on many cancer cell lines including lung cancer (90-93).  These 
data indicated that high doses of isothiocyanates could increase ROS and depleted reduced 
glutathione leading to cell cycle arrest and apoptosis induction. Therefore, through ROS 
generation causing DNA damage, the combination of AIT and SFN mediated G2/M phase cell 
cycle arrest and late apoptosis. 
 62 
Apart from cell viability, cell migration was also observed under treatments as an 
indicator of anti-metastatic/invasive property. Our results showed that A549 migration was 
significantly and synergistically delayed when the AIT and SFN were combined and used to treat 
A549. The higher concentrations of the combination treatment demonstrated a stronger 
synergy by lowering the combination index values. Based on doses of treatments used in this 
cell migration experiment, which is under the same range of those being used in cell viability 
experiment, compounds toxicity could play a role in retarding cell migration. However, 
expression of COX-2 was decreased by AIT and SFN, especially when they are combined 
together. Reducing COX-2 expression could lower the level of prostaglandin E2 (PGE2) 
production, leading to less promotion of tumor growth due to PGE2 activating pathways that 
control cell proliferation, migration, apoptosis, and/or angiogenesis (94). Besides COX-2, STAT3 
also regulates the expression of various genes involving proliferation, apoptosis, angiogenesis, 
invasion, and metastasis (29, 30). Here, we showed that the combination treatment clearly 
decreased phosphorylated STAT3, an active form, as well as MMP-9 which had a function in 
metastatsis to facilitate cells penetration through extracellular matrix (33).   
Our findings show that the combined treatment of ITCs particularly AIT and SFN 
synergistically acted as chemopreventive agents in the inhibition of cancer proliferation and 
progression. These synergistic effects could be due to the fact of low doses of compounds 
utilization which could minimize the development of drug resistance (3). The use of more than 
one compound as a treatment may also act through different mechanisms and provide an 
efficient outcome. However, more information is still necessary for a better understanding in 
the mechanistic actions behind the synergy of compounds in combination. Additionally, the 
concentration ranges of AIT (1.25 - 12.5 µM) and SFN (1 - 10 µM) used throughout this study 
were reasonable in comparison to the concentration of AIT and SFN found in blood of rats and 
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mice after oral application of the compounds (44, 95). This suggests a high possibility to obtain 
similar synergy in an in vivo model as well. 
In summary, the present study has provided evidence supporting potential of the 
combined treatment of AIT and SFN that they synergistically multi-targeted the system of 
proliferation and metastasis of A549 non-small cell lung cancer cells. We have also 
demonstrated cell cycle arrest and apoptosis mediated by the treatments through intracellular 
ROS signaling. These results demonstrate the synergy from AIT and SFN combined treatment 
that can be useful for further in vivo and clinical studies as well as being a guidance to prevent 
lung cancer. 
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CHAPTER 4 
 
SYNERGISTIC ANTI-INFLAMMATORY EFFECTS OF ALLYL ISOTHIOCYANATE AND 
SULFORAPHANE COMBINED BETWEEN THEMSELVES AND WITH OTHER NATURAL BIOACTIVES 
 
4.1 Introduction 
Inflammation can be categorized as both acute and chronic. A regulated inflammatory 
response known as acute inflammation is beneficial in the inducing wound repair and in acting 
against irritants including microbial infections. On the other hand, dysregulation of the 
inflammatory response can induce chronic inflammation leading to many disorders and 
diseases, such as neurodegenerative diseases, cardiovascular diseases and cancers (17).  
During inflammation, many biological events happen including an increased uptake of 
oxygen, which leads to an accumulation of reactive oxygen species (ROS), as well as an 
activation of cellular survival signaling pathways such as nuclear factor-B (NF-B), as well as the 
mitogen-activated protein kinases (MAPKs), extracellular signal–regulated kinase, (ERK), p38, 
and c-Jun N-terminal kinase (JNK), which are known to have crucial roles in inflammation, 
immunity, cell proliferation and apoptosis (11). Activated NF-B translocates into the nucleus 
and upregulates expression of numerous target genes including inducible nitric oxide synthase 
(iNOS), cycloxygenase-2 (COX-2), and inflammatory cytokines (22, 23). iNOS produces nitric 
oxide (NO), in which its excessive amount involves mutagenesis, tumerigenesis, and 
carcinogenesis. Similarly, COX-2 catalyzes biosynthesis of prostaglandins (PGs), which some of 
them, especially PGE2, are associated with cancer (24). Inflammatory cytokines, such as 
interleukin-1β (IL-1β), interleukin-6 (IL-6), and interleukin-10 (IL-10) are also elevated under 
inflammatory conditions (25). Besides, cellular heme oxygenase-1 (HO-1) regulated under the 
nuclear transcription factor erythroid 2p45 - related factor2 (Nrf2), has antioxidant property by 
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catalyzing degradation of pro-inflammatory free hemes and production of anti-inflammatory 
molecules (26, 27).  
Although many bioactive compounds have been found to contribute anti-inflammatory 
properties, the information on utilizing these compounds in combinations to increase the 
efficacy of the therapeutic effects has been limited. Moreover, there has been a considerable 
amount of evidence suggesting the beneficial effects to combination treatment in decreasing 
the risk of toxic side-effects due to too high dose administration and also to reduce the 
development of treatment resistance (3, 63, 66, 67, 96).  
This study investigated the anti-inflammatory effects of the combination between 
sulforaphane (SFN) and allyl isothiocyanate (AIT), which are isothiocyanates (ITCs), between 
themselves and each of them with other bioactives including luteolin (LUT) and curcumin (CUR). 
To this aim, a lipopolysaccharide (LPS)-induced RAW 264.7 macrophages model was used to 
mimic inflammation. After LPS binds to its receptor (toll-like receptor 4), there is an activation of 
common signaling pathway that activate of NF-B, and the upstream kinase cascades (97, 98). 
Therefore, cellular NO, and the levels of several inflammation-related proteins were measured 
and compared under different treatments. The strength of synergy between combined 
treatment of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR were evaluated by the combination index 
(CI) value. 
4.2 Materials and Methods 
4.2.1 Cells Culture and Treatments 
Raw 264.7 macrophages were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA) and were maintained in Roswell Park Memorial Institute (RPMI)-1640 
medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin and 0.1 
mg/mL streptomycin (Mediatech, Manassas, VA, USA) at 37 C in a humidified atmosphere 
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containing 5% CO2. Cells were treated with 2 - 10 µM AIT (98%, Sigma-Aldrich, St. Louis, MO, 
USA), 0.25 - 1.25 µM SFN (> 98%, Quality Phytochemicals Edison, NJ, USA), 5 - 25 µM LUT (98%, 
Quality Phytochemicals), and 2 - 10 µM CUR (Sigma-Aldrich) as single and combination 
treatment with LPS (Sigma-Aldrich, St. Louis, MO, USA) stimulation for 24 hours prior to 
detection in each assay. Compounds were dissolved in dimethyl sulfoxide (DMSO) before further 
dilution in cell growth medium with a final concentration of 0.1 % v/v DMSO. 
4.2.2 Cell Viability and Nitric Oxide Assays 
After 24 hours of RAW 264.7 cell seeding in 96-well plates (1.0 × 105 cells/well), cells 
were treated with LPS (1 μg/mL) with and without the test compounds followed by the 
measurements of cell viability and percentage inhibition of NO production over the following 24 
hours (63). To perform NO assay, 150 L of the culture medium was mixed with 100 μL of Griess 
reagent (2% sulfanilamide and 0.2% N-(1-naphthyl) ethylenediamine dihydrochloride in 
phosphoric acid), the mixture was incubated at room temperature for 30 minutes, and the 
absorbance at 540 nm was measured using a microplate reader (SpectraMax, Molecular 
Devices, Sunnyvale, CA, USA). Cell viability was determined using 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT; Sigma-Aldrich). Cells in each well were incubated 
with 100 L of culture medium containing 0.1 mg/mL MTT at 37 C for 2 hours. MTT containing 
medium was removed prior to the solvation of reduced formazan dye using 100 L/well of 
DMSO, and the absorbance was measured at 570 nm. 
4.2.3 Enzyme-Linked Immunosorbent (ELISA) Assay 
After 24 hours of RAW 264.7 cell seeding in 6-well plates (3.75 × 106 cells/well), cells 
were treated with LPS (1 μg/mL) with and without the test compounds followed by media 
collection over the next 24 hours. Inflammatory cytokines levels which are IL-1β, IL-6, and IL-10 
 67 
were analyzed in cytoplasmic cell fraction or in collected medium by ELISA kits according to the 
manufacturer’s instruction (R&D Systems, Minneapolis, MN, USA; eBioscience, San Diego, CA, 
USA). Absorbance of samples were converted to pg/µg of total protein or pg/mL, respectively.  
4.2.4 Western Blotting 
After 24 hours of RAW 264.7 cell seeding in 100 mm Petri dishes, cells were treated with 
LPS (1 μg/mL) with and without the test compounds. To monitor the expression of p-p65, p65, 
and p-IB, cells were collected at 1 hour after treatments. Other proteins expression was 
monitored after 24 hours of treatments. To collect cells, cold phosphate buffer saline (PBS) was 
used to wash cells that were attaching on the culture plates before detachment using cell 
scraper. Nuclear and cytoplasmic fractions were extracted using NE-PER extraction kit (Thermo 
Fisher Scientific, Waltham, MA, USA). Whole cell lysate was collected in 
radioimmunoprecipitation assay buffer (RIPA buffer) containing protease and phosphatase 
inhibitors (Boston BioProducts, Ashland, MA, USA) into Eppendorf tubes and was placed on ice 
for 20 minutes. Cell suspensions were then sonicated and were lysed on ice for a further 20 
minutes. Supernatants were collected after centrifugation at 20,817 x g for 10 minutes and were 
used to determine protein concentrations by bicinchoninic acid (BCA) protein assay. Equal 
amounts of proteins were resolved by SDS-polyacrylamide gel electrophoresis and transferred 
to nitrocellulose membranes (GVS Filter Technology, Indianapolis, IN, USA). Blocking buffer in 
PBS was used to block non-specific binding of antibodies prior to immunodetection using 
specific antibodies at the manufacturer’s recommended concentrations.  Protein bands were 
visualized using Odyssey system (LI-COR, Lincoln, NE, USA) after incubation with appropriate 
secondary antibodies. Antibodies for p65, p-p65, p-IB, STAT3, and p-STAT3 were purchased 
from Cell Signaling Technology (Danvers, MA). Antibodies for iNOS, COX-2, Nrf2, and HO-1 were 
from Santa Cruz Biotechnology (Dallas, TX, USA). β-Actin antibody (Sigma-Aldrich) and PARP 
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antibody (Cell Signaling) were used as loading controls for whole cell lysate, cytoplasmic 
fraction, and nuclear fraction, respectively. 
4.2.5 Analyses of Synergy   
Synergistic effects of different combinations were analyzed based on Chou and Talalay’s 
method (3) with modifications as previously described (63, 67), using R software. This model is 
used for a constant ratio of compounds combination. When the combination dose of d1 and d2 
provides the same effect x as Drug1 alone at dose Dx,1 and Drug2 alone at dose Dx,2, the 
combination index (equation 1) indicates synergism, additivity, or antagonism of the 
combinatorial effect when the index <1, =1, or >1, respectively. 
Combination index = d1/Dx,1 + d2/Dx,2      (1) 
4.2.6 Statistical Analysis 
All data were presented as mean + SD. The values were compared to the control using 
one-way analysis of variance (ANOVA). The criterion for statistical significance was set at P < 
0.05. 
4.3 Results 
4.3.1 Non-Cytotoxic Effect of Phytochemicals AIT, SFN, LUT, CUR and Their Combinations in 
LPS-Induced RAW 264.7 Cells 
Cell viability assay was performed in RAW 264.7 cells to ensure non-cytotoxicity of 
bioactive compounds used in this study. As shown in Figure 4.1, AIT (2-10 µM), SFN (0.25-1.25 
µM), LUT (5-25 µM), CUR (2-10 µM) and their half dose combinations provided more than 90% 
cell survival compared to LPS control, suggesting non-cytotoxic effect of the treatments. 
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4.3.2 Synergistic Inhibition of LPS-Induced NO Production by the Combination of AIT-SFN, 
SFN-LUT, AIT-LUT, and AIT-CUR in RAW 264.7 Cells 
During LPS stimulation, macrophages released NO, which was an inflammatory 
biomarker used to examine the efficacy of treatments. As shown in figure 4.2A - 4.2D (left 
panel), dose- dependent efficacies of single and combination treatments were observed. AIT (2 - 
10 µM), SFN (0.25 - 1.25 µM), LUT (5 - 25 µM) and CUR (2-10 µM) at the indicated 
concentrations demonstrated the average ranges of 14.6 - 47.5%, 13.2 - 49.1%, 8.6 - 49.1% and 
3.4 - 23.9% NO inhibition, respectively. In terms of reduced dose utilization, the combinatorial 
effect between AIT-SFN (8:1), LUT-SFN (20:1), LUT-AIT (2.5:1), and AIT-CUR (1:1) at their half 
dose serial concentrations provided 20.9 - 53.7%, 11.5 - 55.7%, 17.1 - 67.2%, and 13.0 - 46.2% 
NO inhibition, respectively, all of which had higher efficacy compared to their single treatments.  
To confirm the enhanced effect from using two bioactives in combination, we further 
determined the mode of interaction between each two compounds by using  isobologram 
analysis based on Chou and Talalay’s method (3). In figure 4.2A - 4.2D (right panel), AIT-SFN 
(8:1), LUT-SFN (20:1), LUT-AIT (2.5:1), and AIT-CUR (1:1) showed a synergy with CI less than 1, 
especially the pair of AIT and SFN that could provide the lowest CI of 0.50. 
4.3.3 Inhibitory Effects of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR on LPS-Induced Pro-
Inflammatory Cytokines Production  
IL-6 and IL-1 are cytokines with potent pro-inflammatory properties. To prove that our 
treatments work through these cytokines, ELISA assay was performed. As shown in figure 4.3A - 
4.3D, LPS significantly increased the level of IL-6 released into cell growth medium to 1,461.1 ± 
31.5 pg/mL. Single treatment of AIT (4, and 8 µM), and CUR (4, and 8 µM) did not decreased IL-
6, while other treatments decreased IL-6 in dose-dependent manner. CI of the combined  
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Figure 4.2 Percent inhibition of NO production (Left) and combination indexes (Right) from the 
combination treatments of AIT-SFN (A), SFN-LUT (B), AIT-LUT (C), and AIT-CUR (D) in LPS-
induced RAW 264.7 macrophages. After 24-hour treatments, NO assay was performed on the 
medium. Results are presented as mean ± SD from six replicates.  
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treatments were less than 1, demonstrating synergism between each two compounds at 
indicated doses. Due to a very low concentration of IL-1β found in the cell growth medium, the 
level of this cytokine was determined in the cytoplasmic fraction according to a report of Eder C. 
referring to an active form of IL-1β in cytoplasm before being released to extracellular space 
(99).  
 
 
 
Figure 4.3 Combination effects of AIT-SFN (A), SFN-LUT (B), AIT-LUT (C), and AIT-CUR (D) on 
the level of IL-6 in cell growth medium after 24-hour treatment in LPS-induced RAW 264.7 
macrophages. IL-6 was determined using ELISA. Combination index (CI) ± SE are present in 
parentheses. Results are presented as mean ± SD from triplicates (*P < 0.05). 
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Like IL-6, LPS significantly increased IL-1β to 151.4 ± 17.0 pg/µg protein (Figure 4.4A - 4.4D). 
Single treatments of SFN (0.25, 0.5,1.0 M), LUT (5, 10, 20 M), and CUR (2, 4 ,8 M) dose-
dependently decreased the level of IL-1  induced by LPS. Unlike other bioactives, AIT at the 
concentrations of 4, and 8 M had similar efficacies by lowering IL-1β to 111.6 ± 6.4, 115.4 ± 2.3 
pg/µg protein, respectively. However, not all combined bioactives provided a synergy in  
 
 
 
Figure 4.4 Combination effects of AIT-SFN (A), SFN-LUT (B), AIT-LUT (C), and AIT-CUR (D) on 
the level of cytoplasmic IL-1β after 24-hour treatment in LPS-induced RAW 264.7 macrophages. 
IL-1β was determined using ELISA. Combination index (CI) ± SE are present in parentheses. 
Results are presented as mean ± SD from triplicates (*P < 0.05). 
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decreasing IL-1β. Only some concentrations of SFN-LUT, and AIT-LUT provided synergies with 
less than 1 of CI value, while AIT-SFN, and AIT-CUR combined treatments were antagonisms with 
CI values higher than 1. 
4.3.4 Combination Effects of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR on an Anti-
Inflammatory Cytokine Production Induced by LPS 
To evaluate the potential anti-inflammatory effect of AIT, SFN, LUT, CUR and their 
combinations, the level of IL-10 cytokine was determined in the medium. LPS induced IL-10 
production to 146.7 ± 5.7 pg/mL (Figure 4.5A - 4.5D). Single treatments of SFN (0.25, 0.5, 1.0 
M), and CUR (2, 4 ,8 M) decreased the level of IL-10 in a dose dependent manner with the 
highest efficacy of IL-10 reduction to 9.1 ± 7.2, and 61.5 ± 8.2 pg/mL, respectively. However, the 
dose-dependent effect was not the case for AIT (2, 4, 8 µM), and LUT (5, 10, 20 M), which their 
concentrations of 8 µM AIT and 5 µM LUT most effectively decreased IL-10 to 70.4 ± 5.0, and 
106.3 ± 2.5 pg/mL, respectively. For combination treatments, AIT-SFN was the only pair that 
lower IL-10 in a dose dependent manner to the lowest level of 14.8 ± 25.6 pg/mL. SFN-LUT 
together provided similar efficacy (53.6 ± 21.8 pg/mL IL-10) over the three concentrations. In 
addition, the combination of AIT-LUT and AIT-CUR, which did not provide the dose-dependent 
effects, most effectively decreased IL-10 to 55.5 ± 26.6, and 11.2 ± 6.7 pg/mL, respectively. The 
combination of AIT-SFN (2 µM AIT + 0.25 µM SFN) and AIT-CUR (all three combined 
concentrations) provided a synergistic inhibition of IL-10 production while the combination 
between SFN-LUT, and AIT-LUT provided an antagonism. 
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Figure 4.5 Combination effects of AIT-SFN (A), SFN-LUT (B), AIT-LUT (C), and AIT-CUR (D) on 
the level of IL-10 in cell growth medium after 24-hour treatment in LPS-induced RAW 264.7 
macrophages. IL-6 was determined using ELISA. Combination index (CI) ± SE are present in 
parentheses. Results are presented as mean ± SD from triplicates (*P < 0.05). 
4.3.5 Effects of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR on Protein Expression Under LPS-
Stimulated Condition 
Since the AIT - SFN, LUT-SFN, LUT-AIT and AIT-CUR co-treatment excreted potent synergistic 
inhibitory effects on multiple pro-inflammatory biomarkers, to better understand their 
bioactivities, we investigated the molecular mechanism whether it underlies through NF-B 
pathway which is essential for inflammatory control. Expression of a subunit of NF-B, both 
phosphorylated (p-p65), and non-phosphorylated (p65) forms, p- IB as well as downstream 
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proteins under NF-B regulation which are iNOS, COX-2, and HO-1 was therefore monitored by 
Western blotting to observe any correspondence with the level of NO being released from the 
cells. The results in Figure 4.6 - 4.9A demonstrated that single and combination treatment of 
AIT, SFN, LUT and CUR could decrease the expression level of p-p65 and p65 in the nucleus after 
1 hour of LPS stimulation, especially the combination treatments (AIT-SFN, LUT-SFN, LUT-AIT 
and AIT-CUR) that decreased the expression of nuclear p-p65 as much as 42%, 42%, 19%, and 
39%, respectively. Nuclear p65 was also decreased by AIT-SFN, LUT-SFN, and LUT-AIT as much as 
33%, 39%, and 44%, respectively while it was not decreased by AIT-CUR. Correspondingly, the 
expression of LPS-stimulated p-IB, which occurs when freeing NF-B from the inhibitory 
complex (NF-B - IB binding) in cell cytoplasm was decreased by treatments, especially when 
they were combined. AIT-SFN, LUT-SFN, LUT-AIT and AIT-CUR enhanced p-IB expression after 1 
hour of LPS stimulation in comparison to the effect from each bioactive. This effect was even 
more obvious at hour-24 after LPS stimulation. The combination of AIT-SFN, LUT-SFN, LUT-AIT 
and AIT-CUR could inhibit p-IB as high as 85%, 92%, 64%, and 82%, respectively in whole cell 
lysates (Figure 4.6 - 4.9B). 
Expression of proteins under regulation of the transcription factor NF-B was 
monitored. Pro-inflammatory proteins (iNOS and COX-2) in cell lysates were decreased by 
treatments. The combination of AIT-SFN, LUT-SFN, LUT-AIT and AIT-CUR dose-dependently 
enhanced the reduction of iNOS expression compared to a single treatment by lowering the 
protein expression to 22%, 6%, 18%, and 15%, respectively. The expression of COX-2 was not as 
sensitive to these treatments as iNOS.  The highest concentrations of the combined treatments 
of AIT-SFN, LUT-SFN, LUT-AIT and AIT-CUR only decreased COX-2 expression to 63%, 80%, 63%, 
and 81%, respectively, which this effect was not always dose-dependent. 
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Figure 4.6 Representative Western blots demonstrating combination effects of AIT and SFN in 
LPS-induced RAW 264.7 on the expression of p65 subunit of NF-B in both phosphorylated and 
non-phosphorylated form in the nucleus and the expression of p-IB in cytoplasm after an hour 
of treatment (A). Protein expression of p-IB, iNOS, COX-2, and HO-1 (B) from whole cell lysates 
were monitored after 24-hour treatments. The protein band intensities underneath the blots 
were quantified using Image Studio software. PARP and β-Actin served as internal controls for 
nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are 
representative of at least 3 experiments. 
 78 
 
Figure 4.7 Representative Western blots demonstrating combination effects of SFN and LUT in 
LPS-induced RAW 264.7 on the expression of p65 subunit of NF-B in both phosphorylated and 
non-phosphorylated form in the nucleus and the expression of p-IB in cytoplasm after an hour 
of treatment (A). Protein expression of p-IB, iNOS, COX-2, and HO-1 (B) from whole cell lysates 
were monitored after 24-hour treatments. The protein band intensities underneath the blots 
were quantified using Image Studio software. PARP and β-Actin served as internal controls for 
nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are 
representative of at least 3 experiments. 
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Figure 4.8 Representative Western blots demonstrating combination effects of AIT and LUT in 
LPS-induced RAW 264.7 on the expression of p65 subunit of NF-B in both phosphorylated and 
non-phosphorylated form in the nucleus and the expression of p-IB in cytoplasm after an hour 
of treatment (A). Protein expression of p-IB, iNOS, COX-2, and HO-1 (B) from whole cell lysates 
were monitored after 24-hour treatments. The protein band intensities underneath the blots 
were quantified using Image Studio software. PARP and β-Actin served as internal controls for 
nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are 
representative of at least 3 experiments. 
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Figure 4.9 Representative Western blots demonstrating combination effects of AIT and CUR in 
LPS-induced RAW 264.7 cells on the expression of p65 subunit of NF-B in both phosphorylated 
and non-phosphorylated form in the nucleus and the expression of p-IB in cytoplasm after an 
hour of treatment (A). Protein expression of p-IB, iNOS, COX-2, and HO-1 (B) from whole cell 
lysates were monitored after 24-hour treatments. The protein band intensities underneath the 
blots were quantified using Image Studio software. PARP and β-Actin served as internal controls 
for nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are 
representative of at least 3 experiments. 
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Regarding considerable evidence suggesting links between oxidative stress and 
 inflammation, the expression of HO-1, which is an antioxidant protein known to possess anti-
inflammatory function (11, 27, 100), was monitored in cell lysates through Western blotting. We 
found that both single and combined treatment of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR 
increased HO-1 expression in a dose-dependent manner. The enhanced effect was observed 
from using combined treatments. AIT-SFN, LUT-SFN, LUT-AIT and AIT-CUR maximally increased 
HO-1 expression to 246%, 223%, 568%, and 223%, respectively compared to LPS positive 
control. 
4.4 Discussion 
Utilizing combined bioactives to treat diseases has recently received a significant 
 amount of attention due to possibilities of increasing therapeutic efficacies while reducing 
doses. Major advantages of this strategy are to avoid the risk of overdose toxicity and to reduce 
the development of treatment resistance (3). In this study, we aimed to evaluate the potential 
synergistic anti-inflammatory activities of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR in 
combinations, as well as to investigate their molecular mechanisms in LPS-induced RAW 264.7 
macrophages. 
Cell viability under single and combinatorial treatments were firstly obtained to ensure 
non-cytotoxicity of treatments that were used throughout this study. LPS significantly increased 
NO in cell growth medium but treatments provided at the same time as LPS could significantly 
inhibit NO production in a dose-dependent manner. As a single treatment, SFN (0.25 - 1.25 µM) 
demonstrated higher efficacy than AIT (2 - 10 µM) > CUR (2 - 10 µM) > LUT (5 - 25 µM) 
respecting their efficacies and ranges of dose utilization. Nevertheless, when two of them were 
combined based on their efficacies as AIT-SFN (8:1), LUT-SFN (20:1), LUT-AIT (2.5:1) and AIT-CUR 
(1:1), the synergy in the inhibition of NO production was observed, suggesting the possibility of 
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lowering doses of each compound which would avoid toxicity risk from too high concentrations 
that might bring about metabolic problem (101). Each pair of the combined treatments had 
different trends of CI values over dose ranges, which this effect could be specific to types of 
compounds and ratio of the combination. The combined treatment of AIT-SFN, and AIT-CUR had 
higher CIs when their doses were increased, suggesting a reduction of degree of synergism with 
the increment of concentrations. As the concentration of AIT-LUT combination increased, the CI 
values decreased and became constant, suggesting an increased degree of synergism until a 
certain concentration before reaching constant. CI values of SFN-LUT combination tended to be 
constant over the dose range, suggesting similar degrees of synergism. 
Besides NO, inflammatory cytokines were determined. The reduction of LPS-induced 
pro-inflammatory cytokines, IL-6, and IL-1β, by AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR 
combination were significant and dose-dependent. Synergisms were found from all four 
combined treatments in the inhibition of IL-6 production. Unlike IL-6, not all the combined 
treatments synergistically inhibited IL-1β production. The combination between AIT-SFN, and 
AIT-CUR provided an antagonistic effect on the inhibition of this pro-inflammatory cytokine 
production. Only SFN-LUT, and AIT-LUT combined treatments could provide synergistic decrease 
of IL-1β production. In addition, among four compounds (AIT, SFN, LUT, and CUR) under dose 
ranges that provide similar efficacy on the inhibition of NO production, LUT more obviously 
inhibited IL-1β production compared to other compounds. This information suggests that LUT 
had different anti-inflammatory properties in comparison to AIT, SFN, and CUR. Therefore, using 
LUT to combine with either AIT or SFN could provide a synergism because they enhanced each 
other’s effects potentially through different mechanisms. Besides, the trends of CI values of 
both IL-6, and IL-1β pro-inflammatory cytokines over a dose range were different from that of 
NO inhibition, suggesting partial involvement of these cytokines in NO production. A study in 
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human macrophage demonstrated that not only IL-6, but also IL-10, which is an anti-
inflammatory cytokine, could regulate activation of a transcription factor STAT3 that as a 
consequence was able to regulate expression of iNOS, an enzyme catalyzing NO production (30, 
102). 
In addition to the levels of pro-inflammatory cytokines, we determined the level of an 
anti-inflammatory cytokine, IL-10. Only the combination of 2 µM AIT with 10 µM LUT 
significantly increased IL-10 production. The rest of the treatments, most of them including the 
combined treatments significantly decreased LPS-induced IL-10 production but not in a dose-
dependent fashion. However, CIs indicated a synergism only at low concentrations of AIT-SFN 
combined treatment, and all concentrations of AIT-CUR combined treatments. The combination 
between SFN-LUT and AIT-LUT provided antagonistic effect in the decrease of IL-10 production. 
Although IL-10 has been known to provide anti-inflammatory effects by preventing damage and 
maintaining normal tissue homeostasis, it is not clear whether an elevation of this cytokine 
during infection is a cause or a consequence of high pathogen burden (103). Different levels of 
IL-10 had been produced by compounds and herbal extracts possessing anti-inflammatory 
properties. In LPS-stimulated macrophages some of which, including DG1102 herbal mixture 
(104), N-trans-ϱ-caffeoyl tyramine (105), and the mixtures of recombinant growth factors (106), 
decreased the expression level of IL-10 while the others such as metformin (107), and glyceollins 
(108), increased the level of this inflammatory cytokine. In addition, an anti-inflammatory study 
of dantrolene in LPS-induced RAW 264.7 cells and in LPS-challenged mice exhibited different 
effects on the level of IL-10 (109). Dantrolene, which decreased a pro-inflammatory cytokine 
TNF-α in both in vivo and in vitro, increased IL-10 in the animal plasma but decreased the IL-10 
released by RAW 264.7 cells. These data suggest differential regulation of IL-10 by different 
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compounds under inflammatory events in vitro and in vivo. Thus, further study is necessary for a 
better understanding in the regulations and roles of this inflammatory cytokine.  
To further clarify molecular mechanisms of the inhibitory effects of the combined 
treatments on inflammatory mediators, we investigated the effects of the treatment on the 
activation of a transcription factor, NF-B (p-p5, and p65), and its related proteins in LPS-
stimulated macrophages. Our Western blot results showed that AIT, SFN, LUT, and CUR inhibited 
LPS-induced expression of p-p65, p65, and p-IB which is a feedback control of NF-B activation. 
This observation corresponded with previous studies reporting that AIT,  SFN ,LUT and CUR    
alone inhibits NO production through the NF- B pathway (57, 63, 66, 110). The combined 
treatments of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR enhanced the inhibition of nuclear p-p65, 
and p65, as well as the inhibition of cytosolic p-IB expression after one hour of LPS stimulation 
and bioactive compounds treatment. The enhanced effects from using these combined 
treatments were more obvious in the expression of p-IB after 24 hours of LPS stimulation and 
bioactives application. Similar enhanced effects were observed in protein expression of iNOS 
and COX-2, which are known to be regulated through this pathway (23). The trends of p-p65, 
p65, and p-IB expression were similar to those of iNOS, COX-2, as well as the level of IL-6, and 
IL-1β, confirming the regulatory effects of treatments on the mentioned pro-inflammatory 
proteins through NF-B. Although IL-10 has also been recognized under NF-B regulation, no 
corresponding trend was observed in this study, suggesting other transcription factors playing a 
role over NF-B. Saraiva M., and O’Garra A. reported more than one transcription factor (such 
as NF-B, CREB, and MAF) that control IL-10 expression in macrophage (111).  
In terms of percent reduction of protein expression, iNOS was more sensitive to our 
combined treatments than COX-2, suggesting higher efficacy of the treatments to decrease the 
production of NO over prostaglandins (PGs). This information introduced the idea using a COX-2 
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inhibitor to combine with our treatments for improving anti-inflammatory properties of 
phytochemicals, thus more studies are necessary.  
Studies have shown a sustained relationship between oxidative stress and inflammation. 
ROS can activate the NF-B pathway responding to many cellular activities including 
inflammation (11). Therefore, HO-1, which is an important phase-2 antioxidant protein was 
examined. The results showed that AIT, SFN, LUT, and CUR dose-dependently increased HO-1 
expression. Moreover, their combination between AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR 
enhanced the induction of this protein expression.  
In conclusion, combinatorial treatment of AIT-SFN, SFN-LUT, AIT-LUT, and AIT-CUR 
provided synergistic anti-inflammatory effects by reducing NO production in LPS-induced RAW 
264.7 macrophages. Mechanistic action of this consequence was possibly achieved at least 
partially through the NF-B pathway and cellular antioxidative system as the expressional level 
of p65, p-p65, p-IB, iNOS, COX-2, IL-6, and IL-1 were decreased with an induction of the 
antioxidant proteins HO-1. This information provides an alternative notion of bioactive 
compounds in combinations for inflammation treatment. 
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CHAPTER 5 
 
SYNERGISTIC ANTIOXIDANT EFFECTS OF ALLYL ISOTHIOCYANATE AND SULFORAPHANE ON  
TERT-BUTYL HYDROPEROXIDE-INDUCED RAW 264.7 CELLS 
 
5.1 Introduction 
An overproduction of reactive oxygen species (ROS) causes oxidative stress, in turn 
damaging biological molecules such as lipids, proteins, and DNA, and being implicated in many 
pathological conditions including cardiovascular disease, neurological disorders, diabetes, and 
cancer (11, 12, 19). Under high ROS conditions, the transcription factor Nrf2, a key regulator of 
phase 2 antioxidant and detoxification enzymes, is activated. In cytoplasm, ROS modify protein 
structure of Keap-1 which is a repressor of Nrf2, leading to a dissociation between Keap-1 - Nrf2. 
After that, free Nrf2 is phosphorylated and translocated into the nucleus to bind to antioxidant 
responsive elements, allowing an increased expression of cellular antioxidant proteins (36). 
Similar to Nrf2, the transcription factor NF-B, a key regulator of inflammatory process, 
immunity, cell proliferation and apoptosis, is also activated by ROS (11). NF-B dissociates from 
IB after both of them are phosphorylated. Free phosphorylated NF-B translocates into the 
nucleus and upregulates expression of numerous target genes that control apoptosis (112).  
To increase cellular antioxidant capacity for counteracting oxidative damages, 
antioxidants, especially from natural resources, have received attention and have been 
considered as therapeutic agents. Allyl isothiocyanate (AIT), and sulforaphane (SFN), which are 
dietary isothiocyanates (ITCs) derived from glucosinolates in cruciferous vegetables, have 
demonstrated antioxidant activities through the activation of Nrf2-Antioxidant Response 
Element (ARE) Signaling Pathway. ITCs react with specific thiol groups on Keap-1 and form 
thionacyl adducts, which promotes dissociation of Nrf2 from Keap-1, and allows subsequent 
activation of ARE-driven genes including phase 2 antioxidant and detoxification proteins (46). 
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They also have been shown to decrease ROS during inflammation through both Nrf2 and NF-B 
transcription factors (110, 113). Cell culture studies show that ITCs significantly enhanced mRNA 
and protein expression of phase 2 enzymes heme oxygenase-1 (HO-1) and NAD(P)H: quinone 
oxidoreductase-1 (NQO-1) (83, 114). HO-1 is a part of natural defense mechanisms, which is 
important in preservation of tissue integrity against oxidative stress. By-products of HO-1 
catabolism including carbon monoxide (CO), biliverdin, and bilirubin, have protective effects. CO 
contributes to the attenuation of inflammation while bilirubin is a potent peroxyl radicals  
scavenger (27). NQO-1 demonstrates its antioxidant through reductase activity by converting 
quinone to dihydroquinone. This enzymatic reaction prevents one electron reduction of 
quinones forming semiquinone, a free radical, that can be induced by ROS (115). In an animal 
experiment, ITCs increased tissue levels as well as the activities of quinone reductase, and 
glutathione-S-transferase (GST) (83, 116). Glutathione (GSH) plays a role as a reducing agent to 
maintain thiol groups on intracellular proteins and antioxidant molecules (92). GST catalyzes the 
conjugation of GSH via a sulfhydryl group to electrophilic centers of variety of substrates and 
makes the compounds more water-soluble. This activity detoxifies endogenous compounds such 
as lipid peroxides and enables the breakdown of xenobiotics (117). 
However, the antioxidant study of ITCs in combination, particularly AIT and SFN, and 
their mechanisms of action have not been well defined. The present study compared viability of 
RAW 264.7 cells, which the single or combined ITCs treatment was given before being 
challenged in tert-butyl hydroperoxide (t-BHP), a known ROS producer. The metabolism of t-BHP 
in vivo produces alkyl- and peroxyl radicals, that can initiate lipid peroxidation, deplete 
intracellular GSH, and decrease antioxidant enzymes activities, all of which result in biological 
damages and cell death (118, 119). Thus, using the t-BHP-induced oxidative damage model 
allowed us to evaluate the antioxidant potential of AIT-SFN combined treatments, and 
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compared underlying molecular mechanisms of the combined ITCs with each individual 
compound. We assessed not only cell viability, but also cellular ROS, GSH, GST activity, as well as 
the expression of key transcription factors (Nrf2 and NF-B), and phase 2 antioxidant proteins. 
 
5.2 Materials and Methods 
5.2.1 Cell Culture and Treatments 
Raw 264.7 macrophages were obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA) and were maintained in Roswell Park Memorial Institute (RPMI)-1640 
medium supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin and 0.1 
mg/mL streptomycin (Mediatech, Manassas, VA, USA) at 37 C in a humidified atmosphere 
containing 5% CO2. To investigate the question of whether AIT and SFN in combination can 
attenuate oxidative damage, cells were treated with 0.25 - 1.25 µM AIT (98%, Sigma-Aldrich, St. 
Louis, MO, USA), 0.01 - 0.05 µM SFN (> 98%, Quality Phytochemicals Edison, NJ, USA), and their 
combinations for 24 hours with or without t-BHP (Sigma-Aldrich, St. Louis, MO, USA) 
challenging. Compounds were dissolved in dimethyl sulfoxide (DMSO) before further dilution in 
cell growth medium with a final concentration of 0.1 % v/v DMSO. 
 
5.2.2 Cell Viability Determination 
Raw 264.7 macrophages were pre-treated with AIT, SFN, and their combinations for 24 
hours with or without prior t-BHP challenging at 1000 µM for 3 hours, before subjecting to cell 
viability test. Cell viability was determined using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT; Sigma-Aldrich). Cells in each well were incubated with 100 µL of 
culture medium containing 0.5 mg/mL MTT at 37 C for 1 hours. MTT containing medium were 
removed prior to the solvation of reduced formazan dye using 100 µL/well of DMSO, and the 
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absorbance was measured at 570 nm using a microplate reader (SpectraMax, Molecular 
Devices, Sunnyvale, CA, USA). 
 
5.2.3 ROS Measurement 
ROS measurement is performed in RAW 264.7 cells after t-BHP challenging using 
dichlorofluorescein-diacetate (DCFH-DA) assay. After the removal of cell culture medium, cells 
were incubated with 5 µM DCFH-DA in serum-free RPMI medium without phenol red for 30 
minutes in the dark at 37 C. Excess DCFH-DA that didn’t penetrate into the cells was washed off 
with the medium. Cellular esterase can cleave the ester bond in DCFH-DA yielding DCFH, which 
would be oxidized by ROS and would then become a fluorescent compound, DCF. Fluorescence 
detection at the excitation and emission wavelengths of 485/528 nm was monitored using a 
multi-detection reader (Synergy HT, Biotek Instruments Winooski, VT, USA) after 100 μL addition 
of the medium. Cellular ROS level were relatively determined in comparison to the control and 
the data were normalized by cell viability. 
 
5.2.4 Determination of GSH Level 
Cell lysates were prepared in 100 mM potassium phosphate buffer, pH 7.0, containing 2 
mM EDTA, followed by deproteination of samples using metaphosphoric acid (10% w/v, 
aqueous solution), and triethanolamine. GSH level was determined using a colorimetric assay kit 
(Cayman Chemical, Ann Arbor, MI, USA) according to the manufacture’s instruction. Lysate 
samples were mixed with DTNB (5,5'-dithiobis-2-nitrobenzoic acid, Ellman’s reagent) along with 
other assay cocktail containing cofactor, enzyme mixture, MES buffer, and water. DTNB can 
form a conjugation with GSH in the sample and become GSTNB, which is then reduced by 
glutathione reductase in the cocktail to TNB and reformed GSH. TNB which its level is 
proportional to that of GSH is detectable with absorbance measurement at 412 nm. GSH 
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concentration was calculated based on a standard curve and it was normalized by protein 
concentration.   
 
5.2.5 Determination of GST Enzyme Activity 
Cell lysates were prepared in 100 mM potassium phosphate buffer, pH 7.0, containing 2 
mM EDTA. GST activity was determined using a colorimetric assay kit (Cayman Chemical) 
according to the manufacture’s instruction. Based on the function of GST that conjugate 
toxicants with GSH, CDNB (1-chloro- 2,4-dinitrobenzene) and GSH were added to cell lysates, 
allowing GST in the sample to catalyze conjugation between CDNB and GSH. Kinetic absorbance 
of the conjugation was measured at 340 nm. The rate of absorbance increase was directly 
proportional to the GST activity in the sample, which was finally normalized by protein 
concentration. 
 
5.2.6 Western Blotting 
After 24 hours of RAW 264.7 cell seeding in 100 mm Petri dishes, cells were treated with 
ITCs with or without t-BHP challenging. Cell lysates, nuclear fraction, and cytoplasmic fraction 
were collected and used in Western blotting. To collect cells, cold phosphate buffer saline (PBS) 
was used to wash cells that were attaching on the culture plates before detachment using cell 
scraper. Nuclear and cytoplasmic fractions were extracted using NE-PER extraction kit (Thermo 
Fisher Scientific, Waltham, MA, USA). The whole cell lysate was collected in 
radioimmunoprecipitation assay buffer (RIPA buffer) containing protease and phosphatase 
inhibitors (Boston BioProducts, Ashland, MA, USA) into Eppendorf tubes and was placed on ice 
for 20 minutes. Cell suspensions were then sonicated and were lysed on ice for a further 20 
minutes. Supernatants were collected after centrifugation at 20,817 x g for 10 minutes and were 
used to determine protein concentrations by bicinchoninic acid (BCA) protein assay. Equal 
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amounts of proteins were resolved by SDS-polyacrylamide gel electrophoresis and transferred 
to nitrocellulose membranes (GVS Filter Technology, Indianapolis, IN, USA). Blocking buffer in 
PBS was used to block non-specific binding of antibodies prior to immunodetection using 
specific antibodies at the manufacturer’s recommended concentrations.  Protein bands were 
visualized using Odyssey system (LI-COR, Lincoln, NE, USA) after incubation with appropriate 
secondary antibodies. Antibodies for Nrf2, HO-1, NQO-1 were from Santa Cruz Biotechnology 
(Dallas, TX, USA). Antibodies for p65, and p-p65, which are subunits of NF-B, were purchased 
from Cell Signaling Technology (Danvers, MA). β-Actin antibody (Sigma-Aldrich) and PARP 
antibody (Cell Signaling) were used as loading controls.  
 
5.2.7 Analyses of Synergy   
Synergistic effects of different combinations were analyzed based on Chou and Talalay’s 
method (3) with modifications (63, 67) using R software. This model is used for a constant ratio 
of compounds combination. When the combination dose of d1 and d2 provides the same effect x 
as Drug1 alone at dose Dx,1 and Drug2 alone at dose Dx,2, the combination index (CI; equation 1) 
indicates synergism, additivity, or antagonism of the combinatorial effect when the index <1, =1, 
or >1, respectively. 
Combination index = d1/Dx,1 + d2/Dx,2      (1) 
 
5.2.8 Statistical Analysis 
All data were presented as mean + SD. The values were compared to the control using 
one-way analysis of variance (ANOVA). The criterion for statistical significance was set at P < 
0.05. 
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5.3 Results 
5.3.1 Combination of AIT and SFN Synergistically Attenuated t-BHP-Induced Cytotoxicity  in 
RAW 264.7 Cells 
As shown in figure 5.1A, 1000 µM t-BHP challenging for 3 hours significantly decreased 
RAW 264.7 cell viability from 100% to 17.3 ± 2.4%. On the other hand, ITCs, both as a single and 
combined treatment, significantly reduced t-BHP-induced cytotoxic effects in dose-dependent 
manner. Concentrations of ITCs used in this experiment were based on the potencies of each 
single compound that provided less than 50% protective effect, sparing some space for the 
combination to show off their efficacies. Single treatments of AIT (0.25 - 1.25 µM), and SFN (0.01 
- 0.05 µM) increased cell viability to a range of 17.4 - 42.7%, and 18.2 - 41.8%, respectively, 
while their half-dose combination provided an enhanced effect by increasing number of viable 
cells to a range of 16.4 - 52.4% with a synergy. The CIs of AIT-SFN combined treatment 
calculated based on Chou and Talalay’s method (3), were in a range of 0.50 - 0.74.  
 To ensure non-cytotoxicity of the treatments under normal condition, viability of RAW 
264.7 cells treated with the single or combined ITCs was determined. The results showed that 
without t-BHP, none of the treatments significantly changed viability of RAW 264.7 cells (98.8 - 
107.4%) compared to DMSO control (Figure 5.1B). 
 
5.3.2 AIT and SFN Provided Synergistic Reduction of Cellular ROS Induced by t-BHP 
To further investigate the protective effects of ITCs, the level of intracellular ROS was 
determined. As illustrated in figure 5.2, t-BHP increased 90.3% ROS level in the cells. However, 
treatment exposure prior to t-BHP challenge attenuated cellular ROS. Single treatment of AIT 
(0.25-1.25μM) or SFN (0.01-0.05 μM) significantly diminished t-BHP-induced ROS in RAW 264.7 
cells by 23.5 - 62.8%, and 22.9 - 61.4%, respectively, while their half-dose combination 
synergistically decreased ROS by 38.8 - 71.6% with a range of CI from 0.50 - 0.86. 
 93 
 
Figure 5.1 Viability of RAW 264.7 cells under single and combination treatments of AIT and 
SFN with (A) and without (B) t-BHP challenge. Cells were treated with series of treatment 
concentrations for 24 hours before being exposed to 1000 µM t-BHP for 3 hours. Viability 
measurement was performed using MTT assay. Combination index (CI) ± SE are present in 
parentheses. The data represent the mean ± SD from at least four replicates.  
 
5.3.3 Different Effects of AIT and SFN in Combination Compared between Conditions with and 
without t-BHP Challenge on Cellular GSH Level 
Based on the properties of ITCs that could decrease intracellular ROS induced by t-BHP, 
we continue studying their antioxidant effects by assessing GSH level in the cells under 
conditions with or without oxidative stress. AIT, and SFN concentrations that significantly 
decreased ROS level in the previous experiment were selected for GSH determination. 
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Figure 5.2 AIT, SFN and their combination scavenged t-BHP-induced ROS generation in RAW 
264.7 cells. Intracellular ROS was relatively determined by DCFH-DA assay after 24-hour 
treatments and/or 3-hour t-BHP exposure. Results are presented as mean + SD from four 
replicates. Combination index (CI) ± SE are present in parentheses. (*P < 0.05 vs. untreated 
group) 
 
Figure 5.3 shows that under normal condition, single treatment of both AIT (1 µM) and SFN 
(0.04 µM) did not significantly change cellular GSH level, while their combination treatments 
(0.5 µM AIT + 0.02 µM SFN, and 1 µM AIT + 0.04 µM SFN) significantly decreased GSH level in 
the cells by 9.3, and 19.8%, respectively. Under oxidative stress condition, t-BHP decreased GSH 
level by 37.7%. However, all treatments significantly increased cellular GSH diminished by t-BHP. 
AIT (1 µM) and SFN (0.04 µM), increased GSH level by 27.8, 14.4%, respectively compared to t-
BHP treated control. Their combination (0.5 µM AIT + 0.02 µM SFN, and 1 µM AIT + 0.04 µM 
SFN) dose-dependently increased GSH by 9.8, and 22.8%, respectively. 
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Figure 5.3 Effects of AIT, SFN and their combination on GSH concentration in RAW 264.7 cells.  
Cells were 24-hour treated with different compounds with or without 3-hour t-BHP exposure.  
Total GSH level was determined by Ellman’s reagent. The data represent the mean ± SD from 
triplicates (*P < 0.05 vs. untreated group, #P < 0.05 vs. t-BHP treated group). 
 
5.3.4 Different Effects of AIT and SFN in Combination Compared between Conditions with and 
without t-BHP Challenge on Cellular GST Activity 
GST is a phase 2 enzyme, best known for its ability to catalyze conjugation of reduced 
GSH to xenobiotic substrates for the purpose of detoxification. Regarding the ITCs effect on GSH, 
we also determined the effect of AIT, SFN and their combination on GST activity, under both 
normal and t-BHP stress conditions. As shown in Figure 5.4, under normal condition, only 1 µM 
AIT significantly increased 20.3% GST activity in comparison to the DMSO control. SFN and the 
combination treatments did not significantly change cellular GST activity. Similar to the GSH 
level, t-BHP decreased 16.3% GST activity from the control. However, under oxidative stress 
condition, 1 µM AIT and high concentration of the combined treatment (1 µM AIT + 0.04 µM 
SFN) significantly increased GST activity by 46.7, and 35.0%, respectively. SFN (0.04 µM) and the 
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lower concentration of the combined treatment did not alter cellular GST activity diminished by 
t-BHP. 
 
 
Figure 5.4 Effects of AIT, SFN and their combination on GST activity in RAW 264.7 cells.  
Cells were 24-hour treated with different compounds with or without 3-hour t-BHP exposure.  
GST activity was determined by CDNB assay. The data represent the mean ± SD from triplicates 
(*P < 0.05 vs. untreated group, #P < 0.05 vs. t-BHP treated group). 
 
5.3.5 Effects of AIT, SFN, and Their Combination on Protein Expression 
Protective properties of antioxidants in cells are commonly related to their ability to 
induce cytoprotective enzymes, which includes phase 2 detoxification proteins such as GSH, 
GST, Nrf2, HO-1, and NQO-1. In this respect, we investigated whether AIT, SFN and their 
combination treatments affected the expression of Nrf2 in the nucleus, as well as the expression 
of HO-1, and NQO-1 in the whole cell lysate. The nuclear expression of Nrf2 transcription factor, 
which is a regulator of the anti-oxidant response, was decreased by all ITCs treatment, especially 
by the AIT-SFN combination (Figure 5.5A). Low ITCs concentrations used in this study did not 
change much of HO-1, and NQO-1 expression (Figure 5.5B). The combination of AIT and SFN 
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enhanced a decrement of HO-1 expression under no stress condition, which is similar to the 
cellular GSH level.  
 
 
Figure 5.5 Representative Western blots demonstrating effects of AIT and SFN in RAW 264.7 
cells on the expression of nuclear Nrf2 (A), and the expression of HO-1, and NQO-1 from whole 
cell lysates (B) after 24-hour treatments. PARP and β-Actin served as internal controls for 
nuclear fraction and cytosolic fraction or whole cell lysate, respectively. The results are 
representative of at least 3 experiments. 
 
 
5.3.6 Effects of AIT, SFN, and Their Combination on Protein Expression under Oxidative Stress 
Condition 
To further clarify cytoprotective effects of ITCs, protein expression was monitored after 
t-BHP challenge in ITCs pre-treated cells. Similar to cellular GSH levels, nuclear expression of 
Nrf2 in RAW 264.7 cells was decreased by t-BHP but ITCs pretreatment was able to increase this 
protein expression under stress consition, except the highest AIT-SFN combination that 
decrease the expression in the nucleus (Figure 5.6A). The expression of HO-1, and NQO-1, which  
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Figure 5.6 Representative Western blots demonstrating combination effects of AIT and SFN in 
t-BHP-induced RAW 264.7 cells on the expression of p-p65 subunit of NF-B and Nrf2 in the 
nucleus (A), the expression of p-p65, and p65 in the cell cytoplasm (B), and the expression of 
HO-1, and NQO-1 from whole cell lysates (C) after 24-hour treatments with t-BHP challenge. 
PARP and β-Actin served as internal controls for nuclear fraction and cytosolic fraction or whole 
cell lysate, respectively. The results are representative of at least 3 experiments. 
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are under Nrf2 regulation, was also decreased by t-BHP, but all ITCs pretreatment, especially the 
highest concentrations of AIT-SFN combination, obviously increased expression of these 
proteins in the cells by 11.5-, and 5.8-fold, respectively (Figure 5.6C).  
Besides Nrf2, we also monitored expression level of p65 subunit of NF-B due to its 
sensitivity to ROS (120), and its roles in regulating expression of antioxidant proteins as well as 
in controlling apoptosis (112, 121). Figure 5.6A and B clearly show that t-BHP increased p-p65 
expression in both nucleus and cytoplasm. Most ITCs treatment enhanced p-p65 localization in 
the nucleus but not in a dose-dependent manner, except 0.5 µM AIT that slightly decreased p-
p65 expression in the nucleus. In cell cytoplasm, all ITCs treatments decreased p-p65 with no 
dose-response relationship. Similar to p-p65 in cytoplasm, the expression of p65 was increased 
by t-BHP. Most treatments also increased this protein expression, except the highest 
concentration of AIT-SFN combination that decreased its expression level. 
5.4 Discussion 
To prevent oxidative stress-induced cells or tissues damage, phytochemicals derived 
from our daily diet have received much attention because of their antioxidant properties. ITCs 
which are rich in cruciferous vegetables demonstrate antioxidant activities through an induction 
of Nrf2 transcription factor. However, the antioxidant study of ITCs in combination, particularly 
AIT and SFN, and their mechanistic action underlying antioxidant potential are not sufficiently 
understood. Therefore, we evaluated the enhanced effects of AIT-SFN combined treatment on 
the inhibition of oxidative stress-induced cell death.  
Low concentrations of AIT (0.25 - 1.25 µM), and SFN (0.01 - 0.05 µM), which 
demonstrated no toxic effects in RAW 264.7 cells, were used in this study. t-BHP significantly 
reduced cell viability but pre-treatment with ITCs decreased the number of cells death. As a 
single treatment, SFN demonstrated higher efficacy than AIT according to the lower range of 
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dose utilization in RAW 264.7 cells. In fact, the effect of various ITCs varies among cells and 
tissues. For example, SFN was more effective than AIT in isolated cells, but they had similar 
activity in vivo in terms of phase 2 protective enzymes induction (122). When both of them were 
half-dose combined with the ratio of AIT:SFN being 25:1 based on their efficacies, the synergy in 
attenuation of t-BHP-induced cells death was observed. The combination of AIT and SFN 
provided higher efficacy than each of them being used alone, suggesting the possibility to 
increase the therapeutic efficacy by reducing the dosage in order to avoid the risk of overdose 
toxicity and to reduce the development of treatment resistance (3). 
The synergistic cytoprotective effect from combined AIT-SFN pre-treatment inversely 
correlated with relative levels of intracellular ROS. t-BHP caused a sharp increase 
of ROS generation, which was synergistically attenuated by the combined treatment. These 
results indicated an enhanced antioxidant effects of the combination that protected RAW 264.7 
cells from t-BHP. In fact, pre-treatment of ITCs was necessary for RAW 264.7 cells to obtain the 
antioxidant effect. Without pre-treatment, ITCs application at the same time as t-BHP challenge 
did not recover cell viability (data not shown). This was possibly because ITCs at the 
concentrations used in this study did not possess direct antioxidant effect to scavenge free 
radicals generated by t-BHP. In addition, our in vitro experiments demonstrated that AIT and 
SFN did not have 2,2-diphenyl-1-picrylhydrazyl (DPPH), and 2,2’-azobis(2-amidinopropane) 
(AAPH) scavenging activity (data not shown). However, ITCs alone have been shown to possess 
indirect antioxidant activity by inducing phase 2 antioxidant and detoxification proteins such as 
GSH, GST, HO-1, and NQO-1, through the regulation of Nrf2 transcription factor (83, 114). 
Therefore, we examined these proteins level whether they were affected by the combination 
treatment of AIT and SFN.  
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Recent studies suggested that phytochemicals could directly activate Nrf2 by binding to 
Keap1 through covalent linkages, resulting in the induction of cytoprotective proteins, such as 
HO-1 (123). We investigated the effects of ITCs and their combination under conditions with and 
without oxidative stress.  
Under no stress, the nuclear translocation of Nrf2 was decreased by ITCs, which 
corresponded with cellular protein expression of HO-1, and GSH level that were significantly 
decreased by AIT-SFN combined treatments, while NQO-1 expression was not changed. The low 
concentrations of ITCs (0.04 µM SFN and/or 1 µM AIT) used in this study may convey this effect. 
Other study demonstrated an increased Nrf2 expression in the nucleus when the minimum 
concentration of 5 µM SFN, or 10 µM AIT was applied to NIH3T3 fibroblast (83). The same study 
also showed an increase of HO-1, and NQO-1 expression under 5 µM of AIT or SFN treatment. 
Another support was found in SH-SY5Y dopaminergic-like neuroblastoma that required at least 
2.5 µM of SFN to significantly increased total GSH level (124). However, 1 µM AIT significantly 
increased enzyme activity of GST. These data suggested a possibility of co-regulation of 
transcription factors under this ITC treatment. Morceau et al.(125) verified that NF-B, which is 
sensitive to cellular redox system was involved in GST regulation of K562 leukemia cells. Besides, 
post-transcriptional and/or post-translational modification of GST can affect its enzymatic 
activity, thus further studies are necessary.  
Under t-BHP-induced oxidative stress condition, the nuclear translocation of Nrf2 was 
decreased, which was in accordance with the levels of its downstream proteins GSH, HO-1, and 
NQO-1, as well as GST enzyme activity. However, pre-treatment of cells with ITCs reversed the 
adverse effects of t-BHP, especially AIT-SFN combined treatment that obviously increased HO-1, 
and NQO-1 expression in a dose-dependent manner. ITCs pre-treatment might protect cellular 
proteins against t-BHP toxicity so they could function under stress condition. However, the 
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highest concentration of AIT-SFN combination decreased Nrf2 in the nucleus, suggesting a 
presence of more than one transcription factor besides Nrf2 that regulated these phase 2 
antioxidant and detoxification proteins under ITCs treatment. 
Since NF-B is also involved in cellular redox system, its nuclear and cytoplasmic 
expression was monitored under ITCs treatment. As expected, the expression of NF-B (p65 
subunit) both phosphorylated and non-phosphorylated forms were increased by the pro-
oxidant, t-BHP, in RAW 264.7 cells as a defense mechanism. ITCs treatment did not clearly 
decrease the phosphorylated form (p-p65) in the nucleus but they did clearly decrease p-p65 in 
the cytoplasm although not in a dose-dependent pattern, suggesting partial involvement of this 
NF-B subunit in the protective effects of ITCs. The expression of non-phosphorylated form 
(p65) in the cytoplasm was slightly increased by the treatments except the highest 
concentration of AIT-SFN combination that decreased its expression. Studies have shown that 
NF-kB regulates not only phase 2 proteins, but also apoptosis as either a pro- and anti-apoptotic 
regulator (112, 121), which may explain non-dose-dependent expression level of p-p65, and p65 
in the cells under oxidative stress-induced cell death condition. 
In conclusion, despite the fact that ITCs, particularly AIT and SFN, exert their protection 
against oxidative stress through their indirect antioxidant property, this study shows that these 
two ITCs in combination can provide a synergistic cytoprotective potential against oxidative 
damage by increasing antioxidant effects, decreasing cellular ROS, and increasing viability of 
RAW 264.7 cells. The antioxidant effects of these ITCs including their combination were 
obviously completed through phase 2 antioxidant and detoxification proteins including GSH, 
GST, HO-1, and NQO-1, some of which had more dominant effects than the others, under partial 
regulation of Nrf2, and NF-B transcription factors. This information provides a rationale to 
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develop ITCs preparation for prevention of oxidative stress-related diseases and therapeutic 
applications.  
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CHAPTER 6 
 
CONCLUDING REMAKRS 
As cancer research progresses, we have become increasingly aware that oxidative stress 
and inflammation have been linked to this multi-stage disease during initiation, promotion, and 
progression. The modulation of cellular redox homeostasis holds promise as effective cancer 
prevention and treatment with specificity targetting cancer cells, due to differences in reactive 
oxygen species (ROS) levels between normal and tumor cells. Blocking a source of inflammation 
can enhance cancer immunotherapy (19). This array of events significantly increases the 
likelihood to develop combinatorial anticancer effects through both processes so-called blocking 
and supressing mechanisms. Carcinogenesis can be blocked by prevention of ROS attack on 
DNA, as well as by decrease of prolonged inflammation. Mechanisms that result in cancer or 
tumor suppression include growth inhibition by induction of cell cycle arrest and/or apoptosis 
(19, 41). Accumulating evidence demonstrated a better control of cancer mortality by 
preventing cancer cells from progressing to advanced stages rather than curing when reaching 
malignancies, where available therapeutic options are very limited.  
Consumption of fruits and vegetables has been associated with cancer risk reduction 
due to their containing of dietary bioactive compounds. One major advantage of these natural 
bioactives is that they generally have fewer adverse effects in comparison to pharmaceutical 
drugs after long-term administration. In addition, combination of these phytochemicals have 
demonstrated higher efficacies than isolated compounds, indicating possibilities to improve 
anticancer strategies (2, 41). Since our understanding of molecular mechanisms underlying such 
synergistic effects between compounds is limited, in this dissertation, we demonstrated the 
chemopreventive effects, anti-inflammatory properties, as well as the cytoprotective effect of 
allyl isothiocyanate (AIT) and sulforaphane (SFN) in combination. In addition to the AIT-SFN 
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combined treatment, other phytochemicals including luteolin (LUT), and curcumin (CUR) were 
also used to combine with the aforementioned bioactives and were tested on their enhanced 
anti-inflammatory properties. These bioactive compounds were chosen based on their biological 
properties and their sources which are natural diet-based. AIT and SFN are ITCs found in 
cruciferous vegetables. AIT, also known as mustard oil, can be obtained from mustard seeds 
whereas SFN can be obtained from broccoli. While CUR is rich in turmeric, LUT can be found in 
wide range of diets such as oregano, celery, carrot, and pepper. In this study, combination 
treatments of each two bioactives represented the effects from two different foods 
consumption.   
As shown in Figure 6.1, the combination between AIT and SFN could prevent cancer 
initiation by enhancing each other’s effects as antioxidants. In this case, combined pre-
treatment of AIT (0.25 - 1.25 µM) and SFN (0.01 - 0.05 µM) at a ratio of 25:1 synergistically 
protected RAW 264.7 macrophages against a free-radical generator tert-butyl hydroperoxide (t-
BHP)-induced damage by increasing cell viability, and decreasing cellular ROS. The antioxidant 
effects of these isothiocyanates (ITCs) including their combination were clearly completed 
through phase 2 antioxidant and detoxification proteins including GSH, GST, HO-1, and NQO-1, 
some of which had more dominant effects than the others, under partial regulation of Nrf2, and 
NF-B transcription factors. 
In addition, the combination between AIT-SFN, as well as SFN-LUT, AIT-LUT, and AIT-
CUR possessed anti-inflammatory properties, which could block tumor cells from being initiated 
as well. In this case, the following ranges of concentrations were used: AIT (2 - 10 µM), SFN (0.25 
- 1.25 µM), LUT (5 - 25 µM) and CUR (2-10 µM). AIT-SFN (8:1), LUT-SFN (20:1), LUT-AIT (2.5:1), 
and AIT-CUR (1:1). At these indicated ratios, synergistic decrease of lipopolysaccharide (LPS)-
induced nitic oxide (NO), and pro-inflammatory cytokine IL-6 in RAW 264.7 cells were observed. 
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We also showed that their anti-inflammatory effects partially involved NF-B pathway, which 
regulated expression of other proteins such as iNOS, COX-2, IL-6, IL-1β, and IL-10. In addition, 
the combined treatment also increased the expression of HO-1, which is an antioxidant protein, 
to counteract ROS generated during inflammation. 
 
 
Figure 6.1 Stages in carcinogenesis inhibited by AIT, SFN, and their combination. Adapted from 
reference (18) and experimental results discovered in chapter 3 - 5. 
(*) Phase 2 antioxidant and detoxification proteins induced by ITCs under oxidative stress 
include Nrf2, HO-1, NQO-1, GSH, and GST. 
(**) ITCs decreased iNOS, COX-2, IL-6, IL-1β, and IL-10, partially through the regulation of NF-B. 
(#) Decreased cyclin B1 expression, and increased p21 expression by ITCs led to cell cycle arrest 
at G2/M phase. 
(##) Expression of pro-apoptotic proteins such as p53, cleaved caspase-3, and cleaved PARP 
were decreased by ITCs while expression of an anti-apoptotic protein, survivin, was decreased. 
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In case of cancer suppressing mechanisms, AIT-SFN (1.25:1) combined treatment under 
dose ranges of 2.5 – 12.5 M, and 2 – 10 M, respectively provided synergistic multi-target in 
the system of proliferation and migration of A549 non-small cell lung cancer cells. The treatment 
inhibited cancer cell growth by inducing apoptosis and cell cycle arrest. We demonstrated an 
induction of apoptosis with an increase expression of pro-apoptotic proteins such as p53, 
cleaved caspase-3, and cleaved PARP as well as a decrease expression of an anti-apoptotic 
protein, survivin. We also showed G2/M phase cell cycle arrest by decreasing protein expression 
of cyclin B1 and increasing protein expression of p21. For cell migration, essential proteins such 
as COX-2, and p-STAT3, as well as MMP-9 were decreased.  
Although the concentration ranges and the combination ratios between AIT and SFN 
used in each approach were different, the combined treatment between these two compounds 
could provide synergistic effects as antioxidants, anti-inflammatory, and chemopreventive 
agents. In addition, the concentration ranges of AIT, SFN, LUT, and CUR used in this study were 
reasonable in comparison to the concentration of each compound found in serum of rats and 
mice after an oral administration (ITCs, and LUT), or intravenous administration (CUR) (8, 44, 95, 
126). This information suggests a high possibility to obtain similar synergy in an in vivo model. 
Since the aims of study were completed using three different cell culture models, further study 
using co-culture systems or animal models are necessary to demonstrate how the combination 
treatments perform as in a complex system. It is also good to note that dietary phytochemicals 
including the compounds used in this study can be metabolized in cells and tissues. Therefore, 
further studies of their metabolites will allow us to find their active forms and better approach 
their enhanced effects on cancer prevention and therapy.  
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